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The generation of functional, vascularized tissues is a key challenge for the 
field of tissue engineering. Before clinical implantations of tissue engineered bone 
constructs can succeed, in vitro fabrication needs to address limitations in large-scale 
tissue development, including controlled osteogenesis and an inadequate vasculature 
network to prevent necrosis of large constructs. The tubular perfusion system (TPS) 
bioreactor is an effective culturing method to augment osteogenic differentiation and 
maintain viability of human mesenchymal stem cell (hMSC)-seeded scaffolds while 
they are developed in vitro. To further enhance this process, we developed a novel 
osteogenic growth factors delivery system for dynamically cultured hMSCs using 
microparticles encapsulated in three-dimensional alginate scaffolds.  
 In light of this increased differentiation, we characterized the endogenous 
cytokine distribution throughout the TPS bioreactor. An advantageous effect in the 
  
‘outlet’ portion of the uniaxial growth chamber was discovered due to the system’s 
downstream circulation and the unique modular aspect of the scaffolds. This unique 
trait allowed us to carefully tune the differentiation behavior of specific cell 
populations.  
We applied the knowledge gained from the growth profile of the TPS 
bioreactor to culture a high-volume bone composite in a 3D-printed femur mold. This 
resulted in a tissue engineered bone construct with a volume of 200cm
3
, a 20-fold 
increase over previously reported sizes. We demonstrated high viability of the 
cultured cells throughout the culture period as well as early signs of osteogenic 
differentiation. Taking one step closer toward a viable implant and minimize tissue 
necrosis after implantation, we designed a composite construct by coculturing 
endothelial cells (ECs) and differentiating hMSCs, encouraging prevascularization 
and anastomosis of the graft with the host vasculature. We discovered the necessity of 
cell to cell proximity between the two cell types as well as preference for the natural 
cell binding capabilities of hydrogels like collagen. Notably, the results suggested 
increased osteogenic and angiogenic potential of the encapsulated cells when 
dynamically cultured in the TPS bioreactor, suggesting a synergistic effect between 
coculture and applied shear stress. This work highlights the feasibility of fabricating a 
high-volume, prevascularized tissue engineered bone construct for the regeneration of 
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Chapter 1: Introduction 
 
Over 1.5 million Americans suffer from critically-sized bone defects each 
year, yet treatment remains a major clinical challenge due to the complications 
associated with autologous grafts as well as long recovery periods[1]. While 
engineering efforts to regenerate tissues have advanced, they continue to be hindered 
by inadequate vasculature throughout large constructs, leading to cell death once 
implanted into the defect site[2,3]. Therapies for critical-sized bone defects, which are 
injuries that are unable to regenerate themselves, require high-volume tissue 
engineered constructs with an existing network of nutrient and oxygen delivery to 
maintain cell viability and encourage integration with the host.   Therefore, an in vitro 
method to develop prevascularized tissue engineered bone grafts holds tremendous 
therapeutic potential towards providing a viable regeneration solution. 
To address this issue, we first demonstrate the ability to tune dynamic culture 
conditions in the TPS bioreactor for osteogenic differentiation of 3D encapsulated 
mesenchymal stem cells (MSCs). The roles of applied shear stress and release of 
growth factors were investigated, and the results indicated that these endogenous 
signals help regulate differentiation within a cell population.  
Next, to provide an endothelial network for subsequent vascularization of 
bone, we utilize the inherent link between osteogenesis and angiogenesis to coculture 
endothelial cells (ECs) and osteogenic differentiating MSCs. A variety of in vitro 
coculture methods have been attempted, but few have succeeded as viable long-term 
in vivo options[4–6]. Dynamic in vitro culture environments such as the TPS 
bioreactor mimic in vivo environments by providing mechanical stimulation and 
 2 
 
sufficient nutrient and oxygen transport. Therefore, to emulate their native 
environments during bone ossification and angiogenesis, the cocultured cells can be 
seeded onto three-dimensional hydrogel scaffolds, creating a prevascularized tissue-
engineered bone construct for in vivo applications. These constructs will allow a 
vascular network that can integrate and anastomose to the host vasculature after 
implantation.  
In this work, we leverage the benefits of dynamic culture in the TPS 
bioreactor to provide shear stress to the two encapsulated cell population for the 
application of fabricating a high-volume, patient specific tissue engineered bone 
construct. Four primary objectives of this work include: 
1. Delivery of osteogenic growth factors via PLGA microparticles to hMSC-
encapsulating alginate beads to promote osteogenic differentiation under static 
and dynamic culture. 
2. Characterization of the growth chamber environment of the tubular perfusion 
system (TPS) bioreactor to evaluate the effects of shear and direction of flow 
on the enhancement of osteogenic differentiation of hMSCs.  
3. Fabrication of a high-volume bone tissue engineering construct using the TPS 
bioreactor for the regeneration of critical-sized defects. 
4. Determination of coculture parameters for HUVECs and hMSCs in alginate 




Chapter 2: In vivo techniques and strategies for enhanced 




Tissue engineering expanded rapidly throughout the 1990s based on the 
promise to create new organs and tissue constructs to replace diseased or damaged 
organs [7]. However, two decades later, few products have successful passed the 
Food and Drug Administration (FDA) clinical trials [8]; a feasible transplantable 
organ is still unattainable. More importantly, an organ shortage continues to persist 
because a consistent technique of providing vasculature and integration of tissue-
engineered constructs into the host has not yet been realized [9]. 
Most tissues in the body rely on oxygen and nutrients supplied from blood 
vessels. It has been shown that new blood vessel formation is required once tissue has 
grown beyond 100-200 microns from a nearby vasculature due to oxygen diffusion 
limitations [10].  If implanted engineered tissues cannot obtain the appropriate 
amount of nutrients, the tissue experiences decreased function, nutrient deficiencies, 
or hypoxia, especially at the core of the construct [11]. Therefore, three-dimensional 
constructs depend on rapid development of new blood vessels and vascular networks 
to provide nutrients.  
The development of mature vasculature is one of the major hurdles in the field 
of tissue engineering research, preventing a successful transition from lab bench to 
relevant clinical applications. Without a sufficient supply of oxygen, engineered 
tissue scalability, survival, and integration with the host tissue is extremely limited 
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[9]. It is the hope that with advances in vascularization technology, many of the 
tissue-engineered constructs currently only viable in vitro will be able to become a 
reality. Tissue engineering aims to not only build artificial tissues in the lab, but also 
ultimately enhance or restore function of diseased and damaged tissues. Therefore, 
vascularization of engineered-tissues is a vital next step in moving the field towards 
successful regenerative medicine.  
While a tremendous amount of research is conducted using in vitro methods 
of vascularization of engineered tissues, fewer advances have been made within the 
field of in vivo techniques due to the complex microenvironment, cost, and poorly 
understood synergy between host and implanted cells.  This chapter assesses the 
current state of the field by outlining fundamental approaches taken towards 
developing prevascularized bone tissues in vivo, as well as highlighting their 
advantages and disadvantages. 
2.1.1 Bone tissue engineering 
Tissue loss as a result of injury or disease leads to reduced quality of life, 
especially with an increasing aging population.  However, strategies that encourage 
bone formation by significantly increasing bone density have yet to become available. 
It is a major clinical requirement that has stimulated increasing interest in the tissue-
engineering field to develop new therapies that involve bone regeneration. While 
significant advances have been made combining biomaterials and cells for in vitro 
culture, the field is has seen relatively fewer developments towards clinical trials.   
The gold standard to prevent or treat a fractured non-union is autologous bone 
grafting or delivering bone chips from a secondary donor site into the defect site, 
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where they can then promote and attract other cells responsible for the bone-forming 
process [12]. However, significant donor morbidity such as chronic pain, 
hypersensitivity, infection, and paraesthesia occur in up to a third of the patients [13]. 
In addition, the limited supply and relatively unpredictability of the autologous bone 
grafts have led to the use of alternatives, including allograft. Those can be used for 
larger defects but are limited by the possibility of immune rejection, disease 
transmission, and relatively lower incorporation rate compared to autografts [14]. In 
addition, allografts associated with the reduced cellularity and vascularization 
compared to autologous grafts, leading to poorer bone healing. Xenografts, tissue 
derived from another species, are used less frequently because they have many of the 
same drawbacks in addition to their dissimilarity to human tissue structure and 
function [15]. This in turn led to the development and fabrication of synthetic 
scaffolds, which can be molded into different shapes and sizes to fit the defect site 
[16].  The goal is to engineer constructs with similar properties as natural bone, 
including mechanical strength and structure. However, like many of the other tissue-
engineered organs, bone constructs have been hampered by their inability to remain 
viable in vivo. Unlike other tissues, such as muscle bundles, bone tissue lacks an 
abundant preexisting vascular network, able to rapidly penetrate the scaffold and 
avoid tissue necrosis at the center of the graft. Current methods of graft implantation 
in vivo show slow integration of the host’s vasculature and sufficient nutrient and 
oxygen concentrations only at the host tissue-construct interface. 
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2.2  Scaffold material 
The three-dimensional architecture and design of scaffolds has been shown to 
have a profound effect on the rate of vascularization once implanted in vivo. For 
example, bone scaffolds are typically made out of porous, degradable materials that 
are able to provide the proper mechanical strength during repair and regeneration of 
damaged or disease bone. Some of the design and material property requirements for 
an ideal graft include biocompatibility, adequate pore size, and bioresorbability [6]. 
Biocompatibility describes the scaffold’s ability to support normal cellular activity, 
including molecular signaling, without exhibiting any toxic effect to the host tissue 
[17,18]. For a bone scaffold, this means it must be conducive to cell recruitment and 
subsequent bone formation. It has been shown that pores need to be at least 100 
microns in diameter to allow for diffusion of essential nutrients and oxygen [19].  
Porosity also plays an important role in cell migration and physical communication 
between cells. Unfortunately, increased porosity reduces the mechanical strength of 
the scaffold, affecting the compressive as well as the degradation properties. 
Therefore, finding a delicate balance between architectural and mechanical properties 
is critical during bone scaffold fabrication. Finally, bioresorbability is another 
important factor because the scaffold has to exhibit similar properties as the 
surrounding host tissue, yet degrade at a desired rate to accommodate neovasculature 
and bone formation.  
  In the event that the construct is prevascularized in a well-supplied region of 
the body prior to implantation in the defect site, the scaffolding material is expected 
to remain intact for a significantly longer period of time than if implanted directly 
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into the defect site. A variety of biomaterials have been utilized for this purpose, 
ranging from fibrin [20,21], to poly(lactic-co-glycolic) acid (PLGA) [13,22,23], to 
processed bovine cancellous bone (PBCB) [21]. Many of these scaffolds have been 
evaluated for long-term cytotoxic effects and have shown to have slow degradation 
rates.     
 Several different kinds of hydrogels have been found to facilitate 
osteogenesis. Of those, a few have shown to also promote formation of vascular 
sprouts. Matrigel
TM
 is one of the more popular scaffolds used as a vascularization 
platform [24–26]. It is a decellularized matrix derived from mouse sarcoma cells and 
contains many important proteins such as laminin, entactin, and collagen. Cells 
encounter these structural components in their natural environment, which promote 
cell adhesion and spreading.  In addition, Matrigel
TM
 contains certain growth factors 
that can promote differentiation and proliferation for a variety of cells lines [27,28]. 
However, due to source variance, the actual composition of Matrigel
TM
 can fluctuate 
from lot to lot and results are inconsistent, making Matrigel
TM
 non-ideal for tissue 
engineering techniques [25]. In addition, its xenogenic origin results in unfavorable 
immune responses and could hinder blood vessel formation in vivo. For the purpose 
of bone tissue engineering, growth factor-enriched Matrigel
TM 
has been used as an 
additive to standard scaffolds, such as PLGA, to enhance vascularization [29]. 
Laschke et al. demonstrated that Matrigel
TM
 did not have any effect on the 
biocompatibility of the PLGA scaffold with the seeded cells, but instead improved the 
in vivo ingrowth of new blood vessels from the surrounding tissue.  
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  More complicated, lab-generated scaffolds include modified polyethylene 
glycol diacrylate (PEGDA) hydrogels containing adhesive ligands and encapsulated 
growth factors [30], or protease-sensitive PEG gels with functionalized integrin 
binding sites [31]. Porous scaffolds can be advantageous for vascularization of bone 
tissue, including electrospun scaffolds made out of degradable poly(e-caprolactone) 
(PCL) [32] or silk fibroin [33]. Scaffolds fabricated with a more random porous 
architecture can lead to only partially connected pathways, impeding the formation of 
a dense vascular system. Therefore, scaffolds with well-defined, interconnected pores 
may result in better vessel formation. Such grafts can be best produced with the use of 
rapid-prototyping techniques, which utilizes computer-aided design (CAD) templates 
to print the scaffold layer by layer out of a desired biomaterial [34].  
2.3 Stem and progenitor cells 
A variety of cell types are involved in creating vascularized bone tissue, the 
most obvious being osteoprogenitor and endothelial cells. Recently, mural cells have 
also started to gain more attention as an important component of vascular network 
formation within bone tissue. This section describes different aspects of each cell type 
and their importance to bone vascularization.  
2.3.1 Stem cells 
Stem cells have become the forerunner in the field of tissue engineering due to 
their capability to differentiate into a variety of cell types. Mesenchymal stem cells 
especially have been used more frequently in bone tissue engineering applications. 
Human mesenchymal stem cells (hMSCs) are often used as a source for 
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osteoprogenitor cells because these multipotent cells are isolated from the bone 
marrow and have the ability to differentiate into a variety of lineages to become 
adipocytes, chondrocytes, or osteocytes. In addition, because they reside in the bone 
marrow, they can be obtained fairly easily from an adult patient by way of a bone 
marrow biopsy [35]. For the purpose of bone tissue engineering, the cells can be 
guided towards osteogenesis with the use of mechanical stimulation or growth 
factors, such as bone-morphogenic protein-2 or dexamethasone [36]. In terms of 
immune response, hMSCs are non-immunogenic in vitro, as well as allogenic in vivo, 
making them an ideal candidate for bone regeneration [37]. 
2.3.2 Endothelial cells and source 
  Endothelial cells are a thin layer of cells that make up the interior of blood 
vessels. They have shown to accelerate neovascular formation in many tissue-
engineering constructs by creating blood vessels networks [18,38,39]. In addition to 
their ability to improve vascularization and bone graft survival, endothelial cells are 
able to support osteogenesis, by mediating cell-cell communication via soluble 
factors [40–42] and gap junction proteins [20]. Unfortunately, some of the drawbacks 
of endothelial cells include their limited proliferation ability and the necessity for 
inhibition of the apoptotic response [43].  
  The source of endothelial cells can have an important effect on the success of 
a tissue-engineering construct. There is considerable phenotypic variation among 
cells depending on their source. For example, human umbilical vein endothelial cells 
(HUVECs) are easily obtained from discarded umbilical cords, can be easily 
expanded, and have been shown to be ideal for in vitro applications. However, they 
 10 
 
have resulted in immature and leaky vessels once implanted in vivo [44] On the other 
hand, embryonic stem cells have resulted in some promising outcomes when 
implanted in vivo, including formation of stable microvessels and integration with 
host endothelial cells [27,45]. However, due to the ethical concerns associated with 
them as well as their ability to differentiate into almost every cell type if not tightly 
controlled, their clinical use has been limited. Promising results have recently been 
seen with the use of endothelial progenitor cells (EPCs) [Lin 2000]. EPCs are a small 
population of circulating mononuclear cells that have shown to differentiate into and 
able to keep their endothelial cell characteristic in vitro [46].  
2.3.3 Mural cells 
  Mural cells are a generally used to refer to vascular smooth cells and 
pericytes, which are both involved in the process of blood vessel formation [47]. 
They have been shown to migrate toward sprouting endothelial cells in response to 
vascular endothelial growth factor (VEGF) and are able to help provide a stabilizing 
environment for the cells [47]. They allow for cell-to-cell communication, secrete 
angiogenic factors and extracellular matrix components, and promote endothelial 
blood vessel maturation. The latter involves a series of steps that involve important 
spatial and temporal coordination of the endothelial cells and their signaling 
pathways, such as altering endothelial cell proliferation rate and changing their 
morphology [48].  Several groups have shown the involvement of mural cells in 
angiogenesis [22,23,44], concluding that the recruitment of mural cells greatly affects 
endothelial behavior when cocultured with endothelial cells. Fluorescent microscopy 
shows integration of mural cells into the blood vessel network, which is especially 
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enhanced with the addition of VEGF as a growth factor in vitro [47]. The resulting 
architectural layout of the neovasculature has also been shown to be more mature and 
dense when endothelial cells have been cultured with mural cells.  
 Based on these results, it shows that formation of neovasculature is an 
orchestrated effort of several cell types. Therefore, future experiments may have more 
success if tissue-engineered constructs are implanted in vivo surrounded by a source 
of mural cells to better enable mature blood vessel formation. 
2.4 Cocultures 
  While singular endothelial-derived cell types have been able to demonstrate 
formation of vascular networks, the ultimate goal of generating prevascularized 
tissues may require the coculture of endothelial cells and the target tissue cell 
population. Coculture methods allow for concurrent creation of a vascular network as 
well as the target tissue. The use of the technique has also been shown that 
osteoprogenitor cells show a higher expression of alkaline phosphatase (ALP), an 
early osteogenic differentiation marker, when cocultured with endothelial cells. An 
vast amount of research has been published on coculture techniques for bone tissue 
engineering, ranging from preculture of endothelial cells in vitro followed by the 
addition of the osteoprogenitor cells to the scaffold but prior to in vivo 
implantation[20] (Figure 2.1), preculture of both cell types in vitro and eventual 
implantation into an animal model [32,49–51] (Figure 2.2), to a direct coculture in 
vivo [21,37,52]. However, despite these efforts, there has been limited success with 
complete integration of the implanted scaffold with the functional perfusion of the 






Figure 2.1 In vitro prevascularization using endothelial cells followed by in vivo 
coculture. Scaffolds can be prevascularized in vitro when seeded with endothelial 
cells prior to in vivo coculture with osteoprogenitor cells. a) Endothelial cells seeded 
on scaffold and cultured in vitro. b) Endothelial sprouting and tube formation indicate 
a prevascularized network. c) Prevascularized scaffold is co-seeded with 
osteoprogenitor cells and then implanted in vivo. d) Resulting scaffold shows mature 







Figure 2.2. In vitro prevascularization via coculture of endothelial and 
osteoprogenitor cells.  An in vitro coculture of endothelial cells and osteoprogenitor 
cells can prevascularized a scaffold prior to implantation in vivo. a) Seeding and 
coculture of endothelial cells (red) and osteoprogenitor cells (blue) onto scaffold. b) 
In vitro culturing of construct will result in c) neovascular tube and bone tissue 
formation. d) Once implanted in vivo, the scaffold will become further vascularized 




 There are some general considerations to bear in mind when it comes to 
cocultures. In addition to the cell type, the choice of culture media, seeding density, 
culturing environment, and scaffold architecture are less apparent.  For example, as 
described previously, the source and type of endothelial cells and stem cells can have 
a lasting effect on the engineered bone, with promising results emerging with the use 
of EPCs and hMSCs. Likewise, the ratio of endothelial to osteogenic culturing media 
as well as proportion of endothelial to osteoprogenitor cells will affect vascular 
formation and osteogenic differentiation [20,53]. Ma et al. determined that a 1:1 ratio 
of the two cell populations, cocultured in osteogenic media only, resulted in the most 
mineralization and angiogenic development in vitro.  
 The combination of endothelial and osteoprogenitor cells has been especially 
common in bone tissue engineering cocultures. Both cells types are known to secrete 
specific growth factors that are beneficial for growth and differentiation for each 
other. For example, osteoprogenitor cells secrete VEGF that can be used for 
proliferation and angiogenic processes by endothelial cells [54]. Likewise, endothelial 
cells are known to secrete growth factors such as insulin growth factor-1 [55], 
endothelin-1, and bone-morphogenic protein-2, promoting osteogenic growth and 
differentiation [56]. In addition, it has been shown that the cell-to-cell communication 
between endothelial cells and osteoprogenitor cells can increase the production of the 
early osteogenic marker alkaline phosphatase [38,39].  
 Lastly, evidence from literature shows that mechanotransduction plays a 
synergistic role in the coculture of cells on scaffolds for bone tissue engineering. The 
phenomenon converts a mechanical stimulus into chemical activity, such as a 
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signaling pathway. It is hypothesized that the fluid flow experienced by the cells 
imposed by loading regimes can influence cell proliferation and differentiation 
downstream [57]. However it is still far from being completely understood. 
Therefore, further research should investigate the effect of mechanical stimulation on 
signaling pathways within and between endothelial cells and osteoprogenitor cells 
that lead to enhanced angiogenic and osteogenic effects. Preliminary studies have 
shown that the mechanical stimulation of coupled gap junction proteins between the 
two cell lines can drive osteoblastic differentiation, emphasizing the importance of 
cell-to-cell communication [58].  
2.5 Growth factors 
While scaffold properties such as porosity and degradation rates have shown 
to affect angiogenesis both in vitro and in vivo, a variety of different growth factors 
have been used to in the modification of scaffolds to further promote the formation of 
vascular networks. Promising results have been published about combination 
therapies of cell and angiogenic growth factor deliveries to tissue defect sites [59].  
These additions to the cell culture mimic in vivo conditions, stabilizing the cells and 
protecting them from proteolytic digestion. It has been shown that successful vascular 
network formation requires coordination of not only the right cell type, but also the 
appropriate signaling factors, such as VEGF, delivered at the proper concentration 
and exposure times [9]. Approaches so far have focused on pre-seeding scaffolds with 
growth factors prior to implantation or the incorporation of a slow-release of soluble 
pro-angiogenic factors within the scaffolds.  
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  VEGF is one of the most used pro-angiogenic factors and plays 
multifunctional roles in vascular permeability, repair, and remodeling processes. In 
addition, it maintains vascular structure and function. It has been used extensively in 
a variety of different scaffolds, at different concentrations, and at different time points 
during culture of endothelial cells for the purpose of bone tissue engineering [31,59–
61]. Studies have confirmed that VEGF plays an essential role in the 
neovascularization of tissue and modulates endothelial growth, proliferation, 
migration, and tube formation, therefore making it an important factor in inducing 
angiogenesis.  Bone morphogenetic protein (BMP) is another family of growth 
factors identified to support the use of cells for bone-tissue engineering. They 
promote bone formation by inducing MSCs towards osteoblastic differentiation.  The 
combination of BMP-2 and BMP-7 as osteogenic promoters has shown to be the most 
effective inducer of bone morphogenesis [62]. Yilgor et al. also showed that the 
incorporation of both growth factors lead to more effective differentiation than when 
added individually.  
Although the relationship and interaction between VEGF and BMP has been 
thoroughly examined, angiogenesis’ direct effect on osteogenesis is not yet fully 
understood. It is hypothesized that VEGF is able to elicit two stages (considered early 
and late phases) of angiogenesis while BMP promotes osteogenesis [63]. In turn, 
while undergoing osteogenic differentiation, MSCs secrete more BMP and VEGF 
than when cultured alone, enhancing both processes [37].  
 However, even though the delivery of these growth factors is known to 
enhance vascularization and osteogenesis in constructs after implantation, their 
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dosage and timing must be tightly controlled. Ozawa et al. determined that a 
sufficiently high local VEGF concentration of around 70ng/10
6
 endothelial cells/day 
had a more positive impact on angiogenesis than the same concentration sustained 
over a 28 days [64]. In addition, the group discovered that above 100ng/10
6
 
endothelial cells/day, the resulting unstable blood vessel formation. Excessive 
amounts of VEGF have also shown to lead to severe vascular leakage, tumor growth, 
and retinopathies in neighboring tissues [40]. Geuze et al. explored the effect of 
controlled release BMP-2 and VEGF on bone formation in a large-animal model 
when encapsulated in PLGA microparticles and implanted in critical sized ulnar 
defects in dogs [65]. The group determined that ectopic bone formation was highly 
dependent on the dosage and speed of BMP-2 release, but independent of VEGF 
release.  
2.6 Experimental Setups/Techniques  
2.6.1 In vitro prevascularization 
When cultured with angiogenic growth factors such as VEGF in vitro, 
endothelial cells are able to form prevascular structures before the construct is 
implanted in vivo. For this method, endothelial cells are usually added to the target 
tissue cell population, such that they are cocultured to create a prevascularized 
network within the tissue.  After implantation, the network can then spontaneously 
anastomose with the host’s tissue vascular system and allow for complete perfusion 
of the graft [66]. This method is advantageous because it does not rely on the slow 
integration of the surrounding blood vessel network, which often leads to tissue 
necrosis at the center of the graft. Instead, the pre-established endothelial system can 
 17 
 
directly connect to the surrounding network, allowing for faster blood perfusion.  On 
the other hand, complete in vivo vascularization of the construct can still take days or 
even weeks because the construct’s vascular system is not microsurgically connected 
to the surrounding network following implantation. The effectiveness of in vitro 
vascularization could be improved if micro-surgical methods were used to help with 
the graft anastomosis.  
   Although prevascularization of endothelial cells has shown great promise for 
the formation of blood vessels, has Ghanaati et al. demonstrated that the in vitro 
preculture period of osteoblast cells seeded on scaffolds may not play as prominent a 
role in vascularization as previously thought. The group cultured primary human 
osteoblasts (hOBs) on fibrin scaffolds for 24 hours as well as 14 days before 
implanting the constructs subcutaneously in an immunodeficient mouse model. After 
14 days in vivo, both groups showed significant scaffold vascularization. The 14-day 
preculture group resulted in significantly better penetration of the hOBs throughout 
the scaffold [33], possibly leading to better neo-bone formation and dramatic 
enhancement of the host-derived vasculature. This phenomenon may be explained by 
the hOBs ability to create sufficient extracellular matrix and signaling factors during 
the preculture period, providing a strong pro-angiogenic stimulus once implanted in 
vivo.  
 2.6.2 In vivo prevascularization 
Even though a variety of the body’s complex physiological conditions may be 
mimicked in vitro, it does not provide a complete picture of a scaffold’s potential and 
effect within a defect site. A successful in vivo implantation of a construct will be 
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more revealing of the bone tissue-engineered capability to be translated into a 
relevant clinical application. The location and length of implantation can have a 
significant effect on the resulting growth and maturation of seeded cells. In vivo 
prevascularization can be completed using a variety of different techniques and the 
concept should be applicable to many engineered tissue types. In almost all cases, the 
purpose is to implant an endothelial cell- and target cell-seeded graft into a highly 
vascularized tissue, such as muscle. There, the graft will become naturally become 
vascularized over a period of time, after which it can be harvested and implanted into 
the defect site. 
2.6.2.1 Cell sheet layering 
Another recently developed in vivo vascularization technique is cell sheet 
engineering. It utilized the thermo-responsive properties of poly(N-
isopropylacrylamide) (PIPAAm), which is a well-known temperature-activated 
polymer, to induce detachment of intact cell sheets [67]. Cell sheet engineering was 
originally used for corneal surface reconstruction, blood vessel grafts, and myocardial 
tissue engineering [11]. Since then, the technique has also been utilized in some bone 
tissue engineering applications [68]. A variety of different cells that secrete their own 
extracellular matrix (ECM) can be cultured in monolayer and then recovered within 
their own ECM without the use of a proteolytic enzyme, lifting as an entire sheet. 
Cell sheet-based tissue engineering has been applied for regenerative medicine for 
several different tissues, including myocardial, corneal epithelial, lung, and liver 
tissue [69–72]. Seeding the sheets on scaffolds allows for a three-dimensional 
environment. To determine cellular behavior and study biomaterial immune response 
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in vivo, the construct is implanted subcutaneously into animal models. The cell-sheet 
tissue engineering technique is depicted in Figure 2.3. Pirraco et al. cocultured rat 
bone marrow stromal cells and HUVECs into a cell sheet using thermal-responsive 
culture dishes [51] and then implanted them subcutaneously into the dorsal flap of 
nude mice, demonstrating new bone formation as well as neovascularization by day 7. 
Others have used cell sheet layers to cover scaffolds before in vivo implantation. A 
range of scaffold materials have been used, including coral scaffolds [73], 
hydroxyapatite ceramic scaffolds [74], and polycaprolactone-calcium phosphate 
scaffolds [37]. Layering of cell sheets has also shown improved overall 
vascularization because one cell sheet is added at a time, with 1-3 days of 
subcutaneous vascularization culturing in between. Even though time-consuming, this 
resulted in completely vascularized tissues after several weeks of in vivo culturing 
[68].  
 Even though this technique has been extensively utilized in myocardial tissue 
reconstruction [69], more research should be done to apply the technique to bone 
tissue vascularization where is evident that it can provide efficient blood vessel 
formation within the bone tissue construct. However, further optimization of the 
coculture methods for repair of a bone defect would be necessary. For example, while 
both endothelial cells and osteoprogenitor cells have been shown to form cell sheets 
independently from each other, their behavior and function when cocultured together 
in such form has not yet been investigated. Similarly, the dense and intertwined cells 
within the sheet may inhibit vascularization and bone formation by the respective cell 
types. However, alternating cell type layers could be a possible solution for creating 
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larger vascularized cell constructs. Lastly, a dynamic in vitro culture of layered cell 
sheets could further enhance the endothelial network formation as well as promote 






Figure 2.3 Cell sheet layering used for in vivo vascularization of tissue-
engineered scaffold. Endothelial cells can be cultured into confluent cell sheets and 
used to cover tissue-engineered scaffolds to create a prevascularized network. a) 
Endothelial cell can be cultured on special thermo-responsive tissue-culture plates. b) 
When confluent, the cells will have attached to each other via their extracellular 
matrix forming a cell sheet. c) Several of such sheets can be combined and d) seeded 
onto a scaffold. e) The endothelial cell-sheet- covered scaffold can be implanted 





2.6.2.2 Dorsal skinfold chamber 
Implant observation chambers have been used for decades to monitor living 
tissues. They are frame structures surgically attached to an animal, which allow for 
continuous monitoring of through a glass slide window. Since its invention, the dorsal 
skinfold chamber’s use has been adapted to different animals and applications. Most 
advantageously, observation chambers allow for intravital microscopy of the 
microcirculation of tissue [75]. 
  To create the dorsal skinfold chamber, a small incision is made in the dorsal 
region of the animal to remove the cutis skin layer, around 15mm in mice. The 
remaining layers, consisting of the epidermis, subcutaneous tissue, and a thin layer of 
striated skin muscle are then covered with a coverslip and incorporated into a metal 
frame, usually composed of titanium or aluminum. The frame sandwiches the thin 
layers and keeps them in place using steel nuts as spacers, thus preventing 
compression of the nutritional blood vessels. Within these layers, pieces of 
biomaterial scaffold can be implanted to study their vascularization while cultured in 
the dorsal skinfold chamber. The cover-slipped window allows for intravital 
microscopy of the area and observation of the developing vascular network. Several 
groups have shown that the animal shows no sign of discomfort, including changes in 
feeding or sleeping habits after chamber implantation.   
 This experimental setup has been used to investigate a wide range of scaffold 
and cell combinations to optimize the vascularization of a tissue. For example, 
sphingosine 1-phosphate (S1P) is a bioactive phospholipid, which affects migration, 
proliferation, and survival of endothelial cells and osteoprogenitor cells [44] and has 
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been tested using the dorsal skinfold chamber.  The study evaluated its direct impact 
on the structural remodeling response of the vascularization and subsequent healing 
of a bone defect site and found that sustained release of S1P resulted in enhanced 
luminal diameter of formed vasculatures as well as increased bone formation after 2 
and 6 weeks [44].  
 In order to image the blood vessels more effectively, a contrast agent is often 
injected, such as fluorescein isotheiocyanate-labeled dextran [75], which labels 
plasma. In addition, leukocytes can be traced after intravenous injection of 
fluorescent markers such as acridine orange [75], to better understand the immune 
response to the implanted scaffold. 
One of the major advantages of the dorsal skinfold chamber method is that it 
allows for repeated microscopic analysis over a long period of time, often lasting for 
several weeks, without causing any noticeable harm or discomfort to the animal. The 
subcutaneous location and finely striated tissue provides the ideal environment for the 
purpose of studying the development of a vascular network within a foreign 
biomaterial in vivo.  
  However, some limitations of the dorsal skinfold chamber method do exist. 
For example, due to the size limitations of the animal and the corresponding size of 
the surgical incision, the implanted engineered construct cannot exceed 5mm in 
diameter in order to properly fit in the 15mm-sized chamber [76]. In addition, the 
height, or thickness, of the construct cannot surpass 1mm, so that it does not interfere 
with the closure of the chamber tissue by the coverslip.  Such limitations may prevent 
the use of this in vivo technique for large-scale bone tissue applications. A thicker 
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biomaterial will require a thicker layer of tissue within the chamber, inhibiting image 
quality. Laschke et al. [28] utilized the dorsal skin chamber to evaluate the 
angiogenic response of their nano-sized hydroxyapatite particles mixed with and 
without poly(ester-urethane) and found that capillary sprouts were forming at the 
border of the scaffold, coming from the surrounding tissue, in both groups with no 
significant difference. Druecke et al. also utilized the dorsal skinfold method to test 
the neovascularization within a poly(ether ester) block-copolymer scaffold. Intravital 
fluorescent microscopy and quantitative data analysis of data showed that after 20 
days of implantation, the microcirculation at the border of the construct resembled 
that of the surrounding tissue. However, the center of the graft showed significant 
leakage of plasma, indicating that the newly formed endothelial network was not yet 
mature [77].  
 Several issues would have to be addressed if used for bone tissue-engineering 
applications. For example, the beyond the size limitations, the dorsal skinfold 
chamber does not provide the same bone growth and signaling factors, nor does it 
provide any of the mechanical loading normally applied in a bone defect site. 
Therefore, this technique could be used as prevascularization scaffold, but 
osteoprogenitor cells would be require additional stimulation for bone formation.  
2.6.2.3 Arteriovenous (AV) loops 
An arteriovenous loop is another common in vivo method used to 
prevascularize scaffold prior to the injection or seeding of the target cells. This 
method utilizes the native blood vessel system by forming a shunt loop between an 
artery and a vein using a synthetic graft. This is then enclosed within a chamber that 
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is either empty or houses a tissue-engineered scaffold, which will be vascularized 
over time [Dong 2012]. Within bone tissue-engineering, several people have taken 
advantage of this efficient in vivo method to create a mature endothelial network 
within a scaffold [73,78]. When a processed bovine cancellous bone (PBCB) matrix 
was implanted into an animal model using the AV loop as a vascular carrier, adequate 
vascular density and kinetics demonstrated that capillary sprouting was occurring in 
all parts of the graft even the center. After 8 weeks of in vivo culturing, the group was 
able to demonstrate the first successful vascularization of a solid porous matrix using 
the AV loop technique, followed by bone formation throughout once implanted into a 
bone defect. Dong et al. evaluated vascularization of a natural coral block using the 
AV loop method in a rabbit model. Results showed that natural coral blocks, a 
biocompatible and osteoconductive scaffold, can be vascularized using the AVL 
method and be used for future bone substitute following osteoblast seeding.  
 One of the disadvantages of the AVL technique, however, is that control the 
ingrowth pattern of fibrovascular cells is difficult. Therefore, the vascular network 
may dominate the scaffold structure, especially on the border, minimizing the space 
for target cell seeding. In addition, similar to the dorsal skinfold chamber method, 
following implantation and vascularization in the AV loop, the bone tissue-
engineered scaffold will have to be removed for further culturing and transplantation 
into the actual bone defect potentially resulting in donor site morbidity.  
2.6.2.4 Chick embryo chorioallantoic membrane (CAM) 
One of the innovative techniques used to accomplish prevascularization of a 
scaffold involves the use of the chorioallantoic membrane of a chick egg (Figure 2.4). 
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To obtain this thin membrane, which surrounds the inside of the shell, a fertilized and 
developing egg is incubated at physiological conditions for three days. The egg 
contains a special extraembrionic membrane that supports respiratory capillaries, ion 
exchange, and embryonic vasculature while the chick is developing.  After a brief 
incubation, a circular window is made into the shell and is resealed with tape and 
cultured for an additional 7 days. Then, the tissue-construct is carefully implanted by 
placing it onto the surface of the CAM and then resealing it with cellotape and 
incubating for an additional 8 days, at which point the scaffold is removed for 
analysis. This relative brief culturing period, compared to week to month long periods 
required by other methods, is possible because the CAM undergoes significant 
capillary formation until day 20 of chick embryo development [79].  
  Steffens et al. performed a chick embryo chorioallantoic membrane assay to 
evaluate the angiogenic potential of cell-seeded processed bovine cancellous bone 
and found that vessel formation was visible after 8 days of implantation [21]. 
Similarly, Buschmann et al. used the CAM method to show rapid and homogenous 
vascularization of human adipose-derived stem cells on PLGA/calcium phosphate 
nanoparticles scaffold [80].  
However, one of the major disadvantages of the CAM method is that there 
may be a nonspecific inflammatory response to the implanted biomaterial, altering the 
seeded cell response and behavior. This hurdle may be overcome if the implantation 
is made very early in the development of the CAM, when its immune system is still 
relatively immature. In addition, the CAM method is not ideal for long-term 
monitoring of angiogenesis because the egg will continue to mature and prevent 
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removal of the scaffold [79]. The method of using chick chorioallantoic membranes 
from embryos could also be ethically controversial, although less so than the use of 
human embryonic stem cells. In addition, the combination of human cells with animal 
cells could also lead to disease transmission and rejection after the scaffold is 
explanted from the CAM system and implanted into a bone defect.   
On the other hand, the CAM method could be advantageous, because it 
provides the growth factors and microenvironment necessary to promote 
neovascularization, a process still poorly understood. The rapid vascularization of the 
system provides a simple, inexpensive, and effective method of evaluating the 
response of seeded scaffolds. With a few improvements to the current validation 
strategies used to evaluate the constructs while still implanted, CAM can be a great 
tool to study the biological response to biomaterials and cultured cells before moving 
on to large animal in vivo studies. In addition, it is a relatively easy assay and 
inexpensive to perform, requiring only minimally invasive techniques to obtain a 






Figure 2.4 Scaffold prevascularization using the Chick Embryo Chorioallantoic 
Membrane (CAM) Technique. Scaffolds can be prevascularized without the use of 
endothelial cells by implanting them into fertilized chick embryo eggs. a) A small 
portion of the eggshell is removed, exposing the embryo’s chorioallantoic membrane. 
b) A scaffold is then placed on top of the membrane and the shell is taped up. c) After 
8 days of culture, the scaffold will become vascularized as the chick embryo develops 




2.6 Methods of Validation  
After in vivo transplantation of cell and scaffold constructs, the development 
and functionality of microvascularization need to be evaluated. The most common 
methods of evaluation include histological analysis, imaging techniques, or a 
combination of assays, imaging, and quantitative analysis. 
2.6.1 Histological Analysis 
 Histology has become one of the most common methods of validation for all 
types of tissue engineering applications. For the purpose of tracking and evaluating 
vascularization of bone tissue constructs, this method has been especially invaluable. 
It allows for clear visual validation of the blood vessel formation at the borders and 
the center of the graft. With protein-specific labeling, the implanted endothelial cells 
can be differentiated from those of the host tissue, further indicating the extent of 
neovascularization and integration into the surrounding tissue. Histologically 
processed tissues are most commonly fixed, embedded, and then sliced into micron-
thick sections, after which they can be stained for proteins of interest using primary 
antibodies. Immunofluorescence has also become a popular technique as it allows for 
simultaneous staining and visualization of proteins within the tissue.  
 The bone formation progress can be tracked and visualized with the help of 
histological protein markers. Early osteogenic differentiation proteins include ALP 
and osteoprotegerin (OPN) [74,81], while late markers, such as osteocalcin, 
osteopontin, and collagen type I are expressed during the latter phase of osteogenic 
differentiation [23,37]. In addition, mineralization of the scaffold can be visualized 
using von Kossa or alizarin red stains, which is indicative of calcium deposition and 
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early bone formation [20,23,37]. The development of vascularization can also be 
easily followed by staining for specific angiogenic markers, such as CD31, CD34, 
and von Willebrand factor (vWF) [82]. Certain adhesive proteins are located at 
endothelial cell junctions, including VE-cadherin, connexins, and claudins, and are 
indicative of the tight cell-cell junctions formed between endothelial cells [83] and 
increase in density as angiogenesis progresses.  
 The advantage of a histological analysis is that tissues can be easily visualized 
under bright-field or fluorescence microscopy and it can provide a three-dimensional 
representation based on different sections within the construct. One of the 
disadvantages of performing histology on in vivo cultured constructs, however, is that 
it is a terminal procedure. Therefore, the animal is usually sacrificed in order to 
remove the implanted scaffold after a certain period of time.  
 Histomorphometry is a subsection of histology where the specific change in 
morphology of a structure is especially important, allow for a more macro-scale 
analysis of the entire construct. Computer-aided software is able to quantify the 
formation of new bone on the surface, as well as within the porous structure of the 
graft. More specifically, histomorphometric sections have also been used to quantify 
vessel diameter and vessel density in the scaffold [84]. Images are taken at up to 200x 
magnification to see structures such as formed vessel cross-sections, bone interface 
contact, and bone volume densities. This type of information can be used to evaluate 
bone growth, scaffold integration, and vascular formation. However, similarly to the 
basic histology technique, this method is terminal and does not provide live and 
functional information.  
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2.6.2 Imaging Techniques 
 The combination of in vivo fluorescence microscopy and the dorsal skinfold 
chamber technique has proven to be invaluable to monitoring the inflammatory and 
angiogenic response of the body to a biomaterial. It also provides for a quantitative 
method to assess the formation of vasculature.  
 After capture, images can be analyzed quantitatively offline using a variety of 
software packages. For example, leukocyte-endothelial interaction can be observed 
within the scaffold, indicating the acute inflammatory response to the implanted 
construct, by classifying them into either adherent, rolling, or free flowing cells [28].  
In the case of nanosized hydroxyapatite particles/poly(ester-urethane) scaffolds, the 
number of adherent leukocytes was comparable to the control poly(ester-urethane) 
scaffold, demonstrating that the body had an insignificant immune response to the 
implant.  
 Traditionally, immunostaining has been used to quantify and visualize 
induced vascularization in vivo. However, one drawback to this method is that it is a 
terminal procedure for the animal. Therefore, more advanced and techniques have 
been developed that allow for functional measurement of the architecture and 
perfusion of the newly created vasculature.  
 Three-dimensional scaffolds have been scanned with resolutions of up to 10 
microns using microCT, giving enough detail to determine density, branching, and 
connectivity of the networks [85]. Blood flow has also been studied using laser 
Doppler diffusion imaging [30] as well as the use of transfected cells labeled with 
GFP that can be tracked using a fluorescence microscope [86].  
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 Offline analysis software has been used extensively to quantify microscopy 
images. Wernike et al. determined the functional capillary density of the scaffold 
post-implantation, defined as the length of perfused capillaries per area [52].  The 
group also looked at bone formation properties such as volume of bone pores, bone 
density, and the areas of interaction between bone and vessels. In addition, vascular 
leakage has become an established parameter used to evaluate the success of 
vascularization because it indicates the maturity level of the neovasculature.   
2.7 Limitations in Current Coculture Techniques 
Overall, in vivo techniques have shown that integration of a bone tissue-
engineered construct with the host vasculature can lead to successful anastomosis. 
Full or partial perfusion of the graft has been demonstrated, with endothelial 
sprouting and vessel formation shown after implantation.  
 However, the field of tissue engineering still faces some major challenges that 
need to be addressed before these approaches can be used for clinical applications. 
The importance of the cell source cannot be overlooked, especially due the risk of 
infection and disease transmission. The method of prevascularization must also be 
carefully considered; in vitro pre-seeding of endothelial and osteoprogenitor cells 
onto scaffolds may lead to a basic layout for a vascular network of endothelial cells 
prior to in vivo implantation.  On the other hand, an in vivo prevascularization 
technique may result in a denser vascular network, yet it requires an additional 
invasive surgical step. It is also important to note that if implanted for 
prevascularization for too long, scaffolds often degrade and become too highly 
integrated into the host tissue to remove.  
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Even though most of these bone-engineering techniques are performed in vivo 
to determine the effect of the unique microenvironment provided by the body, few 
actually study the direct effect of implantations into bone defects. While 
subcutaneous implantations into muscle pockets are valuable in terms of determining 
the immune- and cytotoxic effect of the constructs, they do not properly mimic the 
structural and dynamic environment of the bone. Experiments that transplant the 
tissue-engineered constructs into highly vascularized tissues such as the muscle, 
falsely provide high blood flow and the presence of a variety of different types that 
fail to mimic the environment of a bone defect. While successful neo-bone and 
vascular network formations have been demonstrated in these experimental setups, an 
additional transplantation into the actual bone defect site might lead to site morbidity 
and increased risk of infection. These in vivo techniques also result in a longer 
culturing time. Before cells can be seeded onto the scaffolds, they are cultured and 
conditioned in vitro first. Once implanted, it can take weeks to months for the entire 
scaffold to be completely vascularized.  
 Some of the advantages of in vivo vascularization techniques include a more 
accurate microenvironment to evaluate the scaffold and cell construct interactions 
with the surrounding tissue environment compared to current in vitro methods.  Even 
though they have significantly improved the culturing environment to closely 
resemble that found in vivo, there are still many factors that are poorly understood. 
Small-scale in vivo studies, such as the CAM assay, can provide preliminary, yet 
critical data on bone tissue-engineering constructs prior to larger in vivo experiments.  
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  While the field of bone tissue-engineering has made tremendous strides 
towards bringing bench top applications towards clinical use via the use of in vivo 
experiments, there is much left to do until a fully vascularized bone construct can 
successfully heal a bone defect in a patient.  
2.8 Overcoming Current Restraints 
The compilations of studies described in this work address some of the above 
described obstacles in coculture systems. First, the use of primary human cells, such 
as human mesenchymal stem cells (hMSCs) and human umbilical vein endothelial 
cells (HUVECS), provide an essential basis for a bone tissue engineering platform. 
These cells will prevent adverse immune response to non-native cells as well as 
decrease the chance for disease transfer if cells are harvested directly from the patient. 
Second, the in vitro prevascularization of the bone construct will expedite the 
integration of the implant with the host tissue after surgery without adding an addition 
step such as in vivo vascularization with a secondary surgery. The anastomosis of 
organized endothelial cells in vascular networks with existing blood vessel structures 
will provide critical nutrients and oxygen to the bone graft, therefore preventing 
necrosis of the implanted cells.. Additionally, the pre-culture of the graft in dynamic 
culture using a perfusion bioreactor supports the cell function of both cell types 
during coculture, closely mimicking the in vivo environment in regards to  providing 
shear and nutrient supplies. Combined, these steps result in major improvements over 
current bone tissue engineering techniques
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Complete vascularization of engineered tissues is currently a major hurdle in 
the field of tissue engineering, inhibiting successful post-implantation viability. 
Several strategies have been investigated to overcome this problem, often involving 
overexpression of angiogenic and vasculogenic factors such as vascular endothelial 
growth factor (VEGF)[41,58] or combining bioactive scaffolds with encapsulated 
cells [52][40,42] In addition to molecular signals, several other environmental factors 
have been considered to play an important role in promoting vascularization in the 
presence of MSCs. These include environmental effects and interactions with various 
cell populations. Still, complete vascularization of tissue engineered constructs and 
subsequent host integration for clinical applications has yet to be fully realized. 
To overcome these challenges, research has focused on optimizing culturing 
conditions in vitro in preparation for clinical applications. Mesenchymal stem cells 
(MSCs) have become a standard cell population to be cultured with vascular cell 
types due to their ability to act as support cells and accelerate vascularization and 
angiogenesis. The availability and differentiation potential of MSCs makes them a 
popular choice in many developing technologies designed for clinical applications. 
To further illustrate the importance of the role of MSCs in vascularization, a 
survey was conducted by querying leaders in the field of tissue engineering to 
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compile and rank strategies for achieving the clinical development of tissue 
engineering technologies [87]. The analysis of the survey results identified key 
strategic concepts in the future development of the field. The two most important 
strategies were found to be angiogenic control and stem cell science. Thus, in the 
spirit of these findings, we present current concepts and strategies focusing on the 
interactions of MSCs and vascularization. The interactions between MSCs and the 
process of tissue vascularization are intimately related, revealing interdependent roles 
in the goal of developing functional tissue constructs with MSCs. This review will 
evaluate current strategies used to improve vascularization of engineered constructs 
using MSCs and a variety of vascular cell types. The individual roles of these various 
cells in vascularization have been extensively characterized and reviewed, as 
illustrated by Table 1, and we present how environmental conditions and these cell 




Cell Type Function Common Markers Relevant 
Reviews 
MSC  Non-hematopoietic 
stromal cells 
 Can differentiate into 
bone, cartilage, fat, or 
muscle lineages 
 Homing ability for 
tissue regeneration 
CD34-, CD106, 
CD166, CD 146, 
SH2, Stro-1 
[88–91] 
EC  Innermost layer of 
blood vessels 
 Performs crucial 
regulatory roles 




1, VEGFR-2, vWF 
[92–94] 
EPC  Express VEGF 
 Support new vessel 
formation 








Late EPCs: CD31, 
CD133, VEGFR-2, 
VE-cadherin, vWF  
[95–97] 
Pericyte  Wrap around EC 
layer 
 Initiate vessel 
maturation 















3.2 Vascularization interactions with MSCs 
3.2.1 Hypoxia  
The optimal culturing conditions for MSCs have long been studied, with 
oxygen tension being one major characteristic[101]. It has been determined that 
developing embryos have much lower oxygen tension than most normal adult tissue, 
while tissues known to contain stem cells are often in an even lower oxygen 
concentrated environment[102].  This low oxygen tension has been shown to 
maintain the undifferentiated state of mesenchymal stem cells as well as prolong their 
lifespan and proliferation capabilities[103]. However, differentiation into adipocytes 
and osteocytes was hindered at such low oxygen levels and required subsequent 
stimulation at higher oxygen concentrations. This discovery highlights the importance 
of oxygen levels as a critical influence on MSC growth and differentiation.  
Therefore, these culturing conditions have been widely investigated in order to 
optimize vascularization in engineered tissues[104–106]. 
The molecular mechanism of hypoxia has been widely studied, for the 
purpose of neovascularization as well as angiogenesis for cancer metastasis. It has 
been found that hypoxia-inducing factor 1 (HIF-1) is one of the major regulators that 
orchestrates the cellular response to hypoxia[104]. As a transcription factor, it is able 
to modulate vascularization through activation of endothelial growth factors and 
transcription factors. Under hypoxic conditions, HIF-1’s alpha subunit is upregulated 
exponentially, triggering a series of downstream transcription cascades that result 
increased expression of vascular proteins such as VEGF [106]. 
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MSCs have been found in close association with blood vessels in a wide variety of 
tissues.[107,108] Even though MSCs are located very closely to vascular structures, 
they are often still found in a relatively low oxygen environment, which indicates that 
a hypoxic surrounding may be necessary in order to maintain the cells’ 
undifferentiated state[101]. Hypoxia leads to decreased adipogenic and osteogenic 
differentiation,[109,110] triggering the release of angiogenesis factors as well as 
promoting the expression of vasculogenic characteristics and functions in MSCs 
[111,112]. 
With physiological conditions in mind, there are proliferation benefits for 
cells cultured in low oxygen environments. The effects on MSCs’ behavior include 
better survival, proliferation, and differentiation. More specifically, hypoxia can 
stimulate proangiogenic factors in MSCs. For example, VEGF and Interleukin-6 
(IL6) show increased expression after hypoxic stimulation. In addition, MSCs that 
were cultured under physiologically relevant hypoxia (2% oxygen) in a 3D 
environment saw longer proliferation periods as well as expression of increase in 
MSC gene expression than those cultured at normoxic (20%) conditions. [102] 
The level of hypoxia, as well as the time of application, has also shown to be 
important for in vivo vascularization applications. Preculturing of MSCs in hypoxic 
conditions have demonstrated improved angiogenic function once transferred into an 
in vivo environment.[113–115] MSCs  were shown to have enhanced migration rates 
and a number of upregulated growth factors and corresponding receptors, such as 
hepatocyte growth factor (HGF), which is responsible for MSC recruitment to 
damaged and ischemic tissues.[113] These results demonstrate the sensitivity of 
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MSCs to their culturing conditions and the potential to fine-tune their environment to 
enhance vascularization in tissue constructs as well as in vivo transplantations.  MSC 
tissue-constructs cultured at 2% oxygen demonstrated a switch in metabolic pathways 
and exhibited increased proliferation potential compared to those cultured at normal 
oxygen tensions.[116] Changes in total protein levels and ECM expression suggest 
that hypoxia altered the MSC tissue development processes. Furthermore, hypoxic 
conditions are able to better maintain the stemness of undifferentiated MSCs, 
preserving their multi-lineage differentiation ability. These findings indicate that 
oxygen tension may be an important culture parameter in developing in vitro tissues 
using MSCs.  
Nevertheless, while considerable work with hypoxia has been done in the field 
of tissue engineering, there is no convincing evidence that a preculture of cells under 
hypoxic conditions alone will be sufficient to sustain tissue-engineered constructs 
larger than a few millimeters after implantation long term. Therefore, a combination 
of vascularization techniques may be required to complete vascularization in vivo.  
3.2.2 Physical blood flow 
While paracrine and endocrine signals play a large role in controlling MSC 
behavior, mechanical forces and stimuli may also have an important impact on 
vascularization. Specifically, shear stress, a mechanical force generated by fluid flow, 
has been shown to induce MSC differentiation and activation of vasculogenic 
pathways.[117–119] In the body, shear stress is generated by blood flow through the 
endothelium, which applies physical tension to cells. In order to mimic this type of 
mechanical stress in vitro, a flow chamber can supply steady fluid shear stress 
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ranging from 5-30 dyn/cm
2
. Results after dynamic culturing have indicated an 
increase in genetic vascular markers and a decrease in MSC characteristics, 
demonstrating endothelial differentiation of MSCs for potential use in tissue 
engineering applications[120]. 
More specifically, molecular blood vessel formation pathways can be 
triggered by shear stress. It was observed that in some cells, levels of transforming 
growth factor (TGF β) and monocyte chemoattractant protein-1 (MCP-1) greatly 
increased in response to shear stress, while VEGF expression remained unaffected. 
Similarly, studies have identified shear stress receptors on the surface of MSCs that 
may be involved with molecular events related to vascularization. For example, CD31 
receptors activated by shear stress have been shown to increase the recruitment of 
neutrophils and expression of TNF-α, both indicators of early vascularization[121]. 
Several other studies have shown that ion channels, specifically Ca
2+
 channels, are 
sensitive to shear stress and can induce angiogenesis via VEGF-receptor-2 (VEGFR-
2) activation and resulting phosphorylation of p38 and increased expression of 
VEGF[122]. The applied force of fluid flow has also lead to remodeling of the actin 
cytoskeleton, which regulates important intracellular processes and protein 
expressions, indicating the important role that mechanotransduction induced by of 
shear stress plays MSCs’ vascularization pathways[123]. 
Different flow patterns also have an effect on MSCs differentiation. Laminar 
flow has shown increased VEGF production by MSCs but no change in cell 
morphology,[124] while dynamic rotational seeding resulted in vascular tube 
formation of MSCs[125]. The use of shear flow has also become especially popular in 
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tissue-engineered vascular grafts. Using pulsatile flow on a 3D graft, MSCs were 
successfully differentiated into endothelial cells (ECs) as seen through an increase in 
endothelial markers such as platelet-endothelial cell adhesion molecule-1 (PECAM-1) 
and VE-cadherin. In order withstand a range of shear stress to induce endothelial 
differentiation of MSCs in vivo,  tissue engineered scaffolds have been modified with 
a variety of different bioactive molecules to improve cell adhesion and ensure 
immobilization in flow environments[126]. 
Several different factors have been combined in order to promote endothelial 
differentiation for the purpose of vascularization. For example, cultured MSCs under 
shear flow conditions as well as hypoxia  have shown increased production of 
angiogenic factors and formation of microvasculature[119]. Such applications 
validate the complex in vivo culturing environment experienced by MSCs.  
Therefore, the use of flow stimulation may be a crucial step in advancing the field of 
vascularization in tissue engineering because it is able to imitate the dynamic in vivo 
environment most closely.    
3.2.4 Interactions with endothelial cells 
 MSCs are known to adopt a supporting role when mixed with cells derived 
from tissues such as muscle, skin, endothelial, and renal epithelial layers[127]. It has 
been demonstrated that MSCs can promote tumor growth by increasing the secretion 
of pro-angiogenic factors, which enhance blood vessel formation in the surrounding 
areas[128]. With a higher blood and oxygen supply, tumor cells are able to proliferate 
much faster and result in increased tumor size.   
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The interaction between MSCs and ECs has shown to be highly regulated and 
requires precise spatial and temporal control. For example, formation of 
microvasculature is most successful after a delayed addition of MSCs to ECs 
encapsulated in collagen scaffolds and cocultured in an in vitro environment[129]. 
This setup emulates the in vivo environment most accurately because MSCs are 
recruited to the site of vascularization after the ECs have begun the initial formation 
of nascent microstructures[129,130]. 
The interaction between ECs and MSCs has been most pronounced in the 
application of wound healing. MSCs near the location of the wound secrete paracrine 
factors, such as VEGF, to recruit macrophages and endothelial cells, accelerating the 
wound healing process. This process requires a complex series of molecular events 
including cell migration, ECM deposition, angiogenesis and remodeling.[131] At the 
same time, damaged endothelial cells are able to recruit MSCs for the same purpose 
of tissue repair via chemokine receptors found on the surface of MSCs. These MSCs 
were then able to aid in the wound healing process through growth factor release as 
well as differentiation into endothelial cells[132].   
Direct cell-to-cell contact between ECs and MSCs has been investigated to 
understand their signaling pathway and complex interaction. Utilizing a parallel plate 
flow chamber to mimic blood flow conditions, MSCs and human umbilical vein ECs 
(HUVECs) were cocultured with the objective to study the initial steps of 
contact[133]. Results showed rapid extension of the podia, followed by rolling and 
firm adhesion of MSCs to ECs. These results were enhanced when tumor necrosis 
factor-α (TNF-α) was added to the culture, or suppressed when treated with anti-P-
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selectin or anti-vascular cell adhesion protein 1 (VCAM-1), indicating that binding is 
both selectin and integrin dependent. Additionally, combining any of those 
parameters would vary the degree of adhesion of MSCs to EPCs. These collaborative 
pathways indicate that MSCs and ECs are capable of coordinating their rolling and 
adhesion behaviors[132]. 
While ECs and MSCs may interact closely in vivo, their coculture has been 
less successful in vitro, with many microvessels turning out to be leaky and unstable 
once implanted[23]. An improved coculturing system with a higher ratio of 
supporting MSCs, for example, may accelerate the maturation of blood vessels. 
Additionally, a mixed population of vascular cells types will also closer represent the 
native populations necessary for vascularization.  
Interactions with EPCs  
Endothelial progenitor cells (EPCs) circulate the bloodstream and promote 
neovascularization in places of injury, ischemia, hypoxia, and 
tumorigenesis[134,135]. Beneficial interactions between MSCs and EPCs promote 
the development of tubular structures and vascular networks[136,137]. Such 
vascularization and vascular structure formation has been observed in vitro and in 
vivo, lending insight into the mechanisms underlying this process[3,137–139]. MSCs 
interact with EPCs both directly through gap junctions and indirectly through 
paracrine signaling, with major pathways highlighted in Figure 3.1[3]. Direct contact 
between MSCs and EPCs may lead to induced endothelial phenotypes, without the 
addition of exogenous growth factors, in both cell types [3,140]. These cell-cell 
interactions elicit dynamic, temporal changes in co-cultured EPCs and MSCs. 
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Initially, adhesion protein, growth factors and signaling cytokines are upregulated [3]. 
Proteins, such as CDh-5 and PECAM-1, present in vascular cell junctions and 
regulators of vessel permeability are upregulated [3,141]. VEGF, IGF1, and 
angiopoietin1 (ANG-1), responsible for vessel formation, pericyte recruitment, and 
EC differentiation, also experience early, increased expression [3,142,143]. In 
addition to these changes in RNA expression, MSCs have been observed to 
participate with EPCs in forming tube-like structures,[3] further supporting the 
synergistic relationship between MSCs and EPCs in neovascularization.  
In EPC and MSC interactions, bone morphogenetic protein 2 (BMP-2) 
appears to have an important influence on EPCs through chemotactic effects [144]. 
Such effects are bolstered by the elution of angiogenic growth factors from MSCs. 
Secretion of these growth factors from MSCs was found to be dependent on MSC 
exposure to BMP-2 [144]. These secreted factors include placental growth factor 
(PIGF), which is a cytokine associated with the recruitment of EPCs [145]. 
Importantly, paracrine signaling between MSCs and EPCs are strongly dependent on 
the interplay between VEGF and BMP-2. BMP-2 plays an integral role in the 
osteogenic differentiation and function of MSCs. However, BMPs have also been 
shown to stimulate VEGF production. As VEGF stimulation drives angiogenesis, 
BMP-stimulated VEGF promotes angiogenesis [146].  Particularly, BMP-2 has been 
shown to stimulate angiogenesis in fracture-healing models [147,148].  
These interactive pathways have been explored in functional assessments of 
EPC and MSC interactions. EPC and MSC synergistic interactions have been studied 
in critical bone defect repair in rats [137]. The bone defects were repaired with one of 
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the following treatments: autologous bone, β-tricalcium phosphate (β-TCP) as a 
scaffold, MSCs seeded on β-TCP, EPCs seeded on β-TCP, and a coculture of MSCs 
and EPCs seeded on β-TCP. The coculture of MSCs and EPCs produced the highest 
amount of vascularization, demonstrating the synergistic effects of MSCs and EPCs 
in bone repair. Co-transplantation of EPCs and MSCs shows good bone regeneration 
and vascularization potential [138]. In addition to the enhanced vascularization 
demonstrated with the co-implantation of EPCs and MSCs, it is thought that co-
implantation leads to MSCs acting as perivascular mural cells [149]. When cocultured 
with EPCs, MSCs have also shown a committed differentiation toward smooth-
muscle cell and pericyte phenotypes [150]. Differentiation appeared to occur due to 
direct cell to cell contact and extracellular signal-regulated kinase (ERK) signaling, 
demonstrating the various pathways influencing the reciprocal interactions between 
EPCs and MSCs.    
3.2.5 Pericytes, MSCs, and vascularization 
Pericytes are embedded within capillaries, wrapping around ECs within the 
basement membrane [99,151]. While it has been shown that some pericytes, also 
known as mural cells, represent a subpopulation of MSCs, pericytic behavior is not 
characteristic of all cells classified as MSCs [152]. Still, this particular subpopulation 
of MSCs appears to interact with ECs much like bone marrow-derived MSCs, 
utilizing paracrine and direct-contact signaling, and has been extensively reviewed 
[153]. Pericytes utilize a variety of signaling mechanisms that act on ECs, influencing 
vascularization and vessel maturation. Like ECs, pericytes are capable of TGF β 
signaling. TGF β has been directly implicated in pericyte proliferation and 
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differentiation, as well as in the regulation of EC differentiation and proliferation. In 
pericytes, TGF β acts on two receptors: Alk-1 and Alk-5. Alk-1 appears to induce cell 
proliferation and migration, while Alk-5 leads to vessel maturation through 
differentiation and ECM formation [99]. Similar to TGF β signaling, angiopoietin 
secreted by mural cells act on tie receptors receptors expressed by ECs [153]. 
Angiopoietins, acting on Tie receptors expressed by ECs, are secreted by pericytes 
and are crucial to vascular development and remodeling.[142,153] These signaling 
loops have been implicated in vascular remodeling, vascular development, and the 
adhesion of the ECs, MSCs, and ECM [154,155]. 
Several pathways appear to influence perivascular cell recruitment to ECs, as 
illustrated by Figure 3.1. On the surface of pericytes, platelet-derived growth factor 
receptor-beta (PDGFRβ) is expressed, which binds soluble PDGF-BB produced by 
ECs. This particular signaling pathway plays a significant role in pericyte recruitment 
to ECs and has been regarded as the major pathway of pericyte recruitment in 
physiological angiogenesis. In undifferentiated mesenchymal cells, PDGF-BB 
induces mural cell fate [156,157]. By regulating PDGFRβ expression, Notch 
signaling has been suggested to possess a role in mural cell recruitment [158,159]. 
Notch signaling is also crucial for angiogenic sprouting and plays a role in 
endothelial-pericyte interactions [158,160,161]. 
Demonstrating the possibility of other pathways associated with pericyte 
recruitment,  stromal-derived factor 1-a (SDF-1α) it has been recently implicated in 
pericyte recruitment, along with its role in endothelial tube formation and maturation 
[151,162]. Still, pericyte recruitment associated with SDF-1α  may be due to cross-
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talk between SDF-1 α  and PDGF-BB pathways [162]. Another pathway involved in 
pericyte recruitment is through heparin-binding epidermal growth factor (HB-
EGF).[163] HB-EGF, implicated in cardiovascular development, has also been found 
to have protective effect on pericytes by supporting pericyte proliferation and 
minimizing the effects anoxia-induced apoptosis [164]. Several studies have 
demonstrated that HB-EGF pathways may experience crosstalk with PDGF pathways 
[151,165]. Because of the varied pathways affecting pericyte recruitment and 






Figure 3.1 Several cell types are involved in angiogenesis and vascularization. 
Signaling pathways between these cell types direct vascularization and 
differentiation. Differentiation is shown through bold, solid arrows. Dashed lines 




3.2.6 Direct endothelial-like differentiation 
While much of the MSC’s influence on vascularization is primarily through 
paracrine and endocrine effects on other cells, MSCs may also have a direct role in 
vascularization through direct endothelial differentiation. Through endothelial 
differentiation, MSCs have been used in a variety of models, in vitro and in vivo to 
enhance vascularization [166–169]. In vitro, MSCs exhibited endothelial-specific 
markers such as VEGFR-1,VEGFR-2, and vWF after incubation with 2% fetal calf 
serum and 50 ng/ml VEGF [170]. While VEGF may be crucial to inducing arterial 
fate, VEGF alone has also been shown to be ineffective at enhancing or accelerating 
the endothelial differentiation of MSCs [171]. Still, further angiogenesis tests 
demonstrated the functional behavior of conduits formed by the MSCs [166]. 
Conversely, ECs have been found to differentiate into MSCs [172,173]. EC-derived 
MSCs have displayed the capability to differentiate into adipocytes, chondrocytes, 
and osteoblasts [173]. Such differentiation could be induced by TGFβ2 or BMP4. The 
relationship between EC and MSC differentiation pathways provide alternative 
approaches to studying and solving issues of vascularization in tissue engineered 
constructs. 
In addition to utilizing natural growth factor, researchers are investigating 
synthetic chemicals and drugs to induce endothelial differentiation of stem cells. 
Chemical small molecules have been used to induce mouse embryonic stem cell 
(ESC) differentiation into ECs. For example, the compound R-ABO effectively 
induced ESC differentiation into ECs via upregulation of a molecule acting upstream 
of fibroblast growth factor 2 (FGF-2).[174] Another study used a DNA 
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methyltransferase inhibitor to induce endothelial differentiation of ESCs via 
epigenetic activation more efficiently than tradition VEGF treatment strategies [175]. 
Extending these strategies to MSCs, one study treated adipose-derived MSCs with an 
epigenetic drug, BIX-01294 [176]. Treatment resulted in significantly increased 
expression of several markers and factors associated with endothelial cells and blood 
vessel formation, including VCAM-1, PECAM-1, vWF, VEGFR-2, PDGF, and 
ANG-1. Continued research into synthetic chemical induced EC differentiation could 
improve the efficiency of differentiation and thereby reduce the costs of therapeutic 
MSC differentiation strategies. 
In addition to soluble natural and synthetic chemicals, microenvironmental 
effects are critical to MSC behavior and fate. Substrate topology and mechanical 
properties are crucial determinants of cell function and fate [177–179]. For example, 
MSCs differentiated along neural, myogenic, and osteogenic lineages, dependent on 
the modulus of two-dimensional substrate gels on which MSCs were cultured [180]. 
MSCs cultured using either vasculogenic and nonvasculogenic and seeded on three-
dimensional (3-D) tubular collagen scaffolds experienced EC and SMC 
differentiation [181]. Thus, it is apparent that the 3-D microenvironment can 
effectively induce differentiation even without the influence of soluble growth 
factors. MSCs have also been seeded on three-dimensional nanofiber matrices with 
elastic moduli tuned to ranges that corresponded with the intima and media layers of 
blood vessels [182]. The tuned nanofiber matrix moduli enabled control of MSC 
differentiation into ECs or SMCs. Controlling MSC differentiation into ECs has also 
been tuned by modification of fibrinogen with various PEG derivatives to achieve a 
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range of mechanical and physical properties [183]. Adjusting the properties of these 
substrates resulted in drastic alterations in cell morphology, gene expression, and 
overall transdifferentiation of MSCs to an EC-like phenotype.  Thus, when inducing 
differentiation of MSCs to an endothelial phenotype, it is crucial to consider both 
chemical and physical microenvironmental conditions for therapeutic applications. 
In an example of therapeutic benefit, researchers utilized MSCs’ ability to 
differentiate into ECs in an in vivo canine chronic ischemia model [169]. Injected 
MSCs were found to have differentiated into SMCs and transdifferentiated into 
endothelial cells, as suggested by the luminal location of the MCSs and their 
expressed factor VIII [169]. Such transdifferentiation may have led to the higher 
capillary density observed in the MSC-treated canines.  Canine MSCs have also been 
seeded on decellularized arterial matrices and cultured in pulsatile flow bioreactors 
[184]. These MSCs cultured on the matrices expressed vWF and oriented themselves 
in the flow direction. Endothelial differentiation of MSCs  can be promoted by  of 
growth supplements and shear force [166]. While growth supplement administration 
and shear force exposure were not sufficient alone to differentiate MSCs, the cells 
produced an endothelial gene expression profile, including CD31, KDR, and vWF, 
and exhibited morphology consistent with ECs, when seeded in Matrigel. In addition, 
these MSCs, after growth supplement and shear force priming, were capable of 
forming a functional capillary network in 3D culture environments, both in vitro and 
in vivo. These results demonstrate the complex environment that leads to MSC to EC 
differentiation, which may be difficult to replicate in an in vitro experiment. Still, 
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these studies validate the potential capability of MSCs to be used as a cell source for 
not only supporting vascular cells, but also directly vascularizing tissue constructs. 
3.3 Applications 
As with most developing tissue engineering obstacles, several challenges 
remain in translating the fundamental relationship between MSCs and vascularization 
into clinical applications. There is a need to define and develop optimized culture and 
3-D microenvironmental conditions for MSCs and any vascular cells that may be 
included in order to promote healthy tissue development and vascularization.  
Utilizing these cells in a clinical environment must involve a careful understanding of 
the safety issues involved with the biomaterials chosen, source of the cells, and any 
modification (genetic or otherwise) to the cells. While much work has been 
performed in applying MSCs and vascularization in in vivo experiments, a complete 
understanding of the signaling pathways and cell types involved has yet to be 
elucidated. Clarifying these more basic fundamental questions will provide greater 
insight into the results and advancements made in therapeutic in vivo applications. 
For example, considerable debate still remains regarding the precise identities and 
subtypes of EPCs and pericytes, and, as such, their functional relationship with MSCs 
must be more closely examined [96,100].  To complement the growing understanding 
of these relationships, a variety of strategies have been utilized to take advantage of 
both MSCs influence on vascularization and vascular cells’ influence on MSCs. 
Many of these concepts directly incorporate one or more signaling pathways, various 
vascular cell types, and deliberate cellular microenvironment design to reach these 
ends as summarized in Fig. 2. 
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3.3.1 MSC 3-D microenvironment 
MSCs may be seeded onto scaffolds, injected, or implanted on their own to 
improve tissue vascularization. To examine the perivascular therapeutic potential of 
MSCs, MSCs were embedded in alginate beads and implanted the beads in ischemic 
mice.[185] Beads were implanted in the perivascular space around the femoral artery. 
The implantation of beads containing MSCs activated proangiogenic signaling 
pathways leading to the activation of VEGF-A. Through these mechanisms, the 
perivascular MSCs appeared to support neovascularization, significantly improved 
blood flow, increased tissue oxygenation and reduced toe necrosis. In another 
application, bone marrow-derived MSCs were seeded into pullulan-collagen 
hydrogels and implanted in a murine model simulating an excisional wound [186]. 
MSCs seeded on the hydrogels best secreted angiogenic factors compared to those 
grown in standard culture conditions. Once implanted, the seeded MSCs were 
discovered to have differentiated into fibroblasts, ECs, and pericytes, while also 
demonstrating significantly increased angiogenesis in wounds treated with the MSC-
seeded hydrogels. 
To bolster cell-cell communication, the three-dimensional microenvironment 
must be considered.  Such an environment may directly affect cell-cell signaling, 
survival, proliferation, and differentiation. For example, MSCs aggregated into three-
dimensional spheroids produce higher amounts of VEGF and FGF-2 [187]. Because 
of these effects, three-dimensional MSC spheroids were seeded onto porous 
polyurethane scaffolds [188]. Compared to non-seeded scaffolds and scaffolds seeded 
with individual MSCs, MSC spheroid seeded scaffolds demonstrated improved 
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scaffold vascularization and higher microvessel functionality. In the absence of 
biomaterial scaffolds, simply encouraging 3D organization of MSCs also enhances 
MSC survival and, subsequently, vascularization. For example, in both in vitro and in 
vivo environments, MSCs transplanted in spheroids produced by a hanging-drop 
method improved the viability of the MSCs [189]. MSC spheroid transplantation, 
compared to MSCs from monolayer, resulted in increased microvessel formation and 
reduced limb loss and necrosis in ischemic mice. While the 3D environment may 
increase paracrine signaling and function in the MSCs, the spheroids may also have 
allowed for longer MSC residency in the tissues compared to MSCs transplanted 
from monolayer. 
Culturing and implanting MSCs in a 3-D microenvironment appears to 
improve MSCs’ promotion of angiogenesis and neovascularization. These strategies 
appear to work well on small implant sizes and when used in a more supportive role, 
like perivascular delivery to ischemic tissues, instead of a direct role, such as 
osteogenesis in a critical-sized bone defect. For larger structures, culturing 
unmodified MSCs alone has not been sufficient for promoting tissue vascularization. 
3.3.2 Genetic modification of MSCs 
To bolster the natural influence of MSCs on vascularization, MSCs have been 
genetically modified to expedite and improve vascularization and tissue formation. 
Bmp2 gene-modified MSCs and EPCs were delivered in injectable calcium 
sulfate/alginate scaffolds, providing drastic increases in osteoblast differentiation and 
endothelial differentiation, resulting in increased bone and vascular formation [190]. 
Another genetic modification strategy involved modifying MSCs to express VEGF 
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[191]. The increased expression of VEGF led to a 3-fold increase of vascular density 
compared to control MSC-seeded grafts. However, the increased VEGF levels 
resulted in decreased quantities of bone formation and increased osteoclast 
populations. Such information demonstrates the importance of carefully weighing the 
benefits of methods to improve vascularization, while ensuring minimal deleterious 
effects of MSC contributions to bone formation and homeostasis. Relying on genetic 
modifications of MSCs introduces additional safety concerns, increasing the barriers 
to clinical applicability. 
3.3.3 Combinatorial cell seeding and scaffold incorporation  
Besides utilizing MSCs alone, a variety of strategies have incorporated the 
implantation of ECs, EPCs, and pericytes to better improve engineered 
vascularization. One group seeded MSCs and EPCs in macroporous 
polycaprolactone-tricalcium phosphate scaffolds and subsequently cultured within a 
biaxial bioreactor [192]. Interestingly, scaffolds cultured within the bioreactor did not 
demonstrate vessel formation as shown in static controls, despite greater 
mineralization. Despite these in vitro results, dynamically cultured scaffolds 
displayed both earlier vasculogenesis and increased bone formation in vivo compared 
to statically cultured constructs. Dynamically cultured scaffolds yielded 1.2- and 2.3- 
fold more capillary formation than static and acellular controls, respectively. 
Prevascularization of tissue engineered bone constructs through the insertion of a 
vascular bundle have been found to augment both new bone formation and vessel 
formation once implanted in β-TCP scaffolds seeded with MSCs [193]. In scaffolds 
with MSCs and inserted vascular bundles, VEGF levels were markedly increased 
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over control constructs. Combinatorial cell seeding appears to be a good potential 
strategy for ensuring adequate vascularization in implanted tissue constructs. 
Prevascularization of tissue constructs, though, could take considerable time and 
effort before implanting the scaffold in a clinical application, in addition to the safety 
concerns associated with autologous cell seeding. 
3.3.4 Combining Strategies 
Scaffold design and modification, genetic modification, combinatorial cell 
seeding and other vascularization techniques are often not uniquely applied. For 
example, the close relationship between MSCs and pericytes was used to design a 
scaffold-free construct of MSCs, ECs, and perivascular-like cells [194]. The 
perivascular-like cells were differentiated from MSCs and seeded onto a MSC 
monolayer, along with ECs. EC and perivascular-like cells self-assembled into 
colonies in vitro and vascularized the osteogenic tissue sheets when implanted in vivo 
when seeded by themselves.  Using MSCs for perivascular-like and osteogenic 
functions proved to stabilize the vascular network formed in vivo, demonstrating the 
importance of cross-talk between all these cells during the vascularization process. 
Likely, successful tissue engineered constructs to support vascularization will 
necessarily incorporate multiple strategies discussed here.  
3.4 Conclusion 
While tremendous strides have been made in understanding the complex 
interactions between MSCs and vascularization, the need for vascularizing MSC-
derived tissue constructs still demands the continued development of current and 
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future strategies to enhance the clinical potential of MSC-based therapies. Such 
strategies will not only entail incorporating vascular cells to support MSCs; 
successful strategies will likely utilize MSCs’ beneficial paracrine and autocrine 
effects on vascular cells to further improve and expedite vascularization. 
Vasculogenic MSC pathways can be bolstered through methods such as careful 
scaffold design, growth factor immobilization, or genetic modification. The optimal 




Chapter 4:  Synergistic effect of sustained release of growth 




4.1 Introduction  
  Critical bone defects affect more than 1.5 million Americans each year [195]. 
The current gold standard of treatment involves autologous bone transplants, which 
still suffer from several limitations. Therefore, tissue engineering strategies are being 
explored and include cell seeded 3-dimensional scaffolds that can be cultured in vitro 
to promote proliferation and differentiation of stem cells prior to implantation into the 
injury site. However, in vitro static culture techniques of 3D tissue engineering 
scaffolds face several obstacles including low oxygen and nutrient concentrations 
toward the center of the scaffold, leading to cell death [196]. A bioreactor is often 
used to overcome this limitation of nutrient transfer. A bioreactor can support or 
expand a population of cells through dynamic culture in a controlled environment. 
Different bioreactors systems have been proposed in bone tissue engineering, 
including spinner flasks [26,197,198], rotating wall bioreactors [199], and perfusion 
systems [200,201]. Perfusion systems effectively provide media (at laminar flow 
regimes) throughout the scaffold, enhancing nutrient transport, while exposing cells 
to fluid shear stresses shown to be influential in osteogenic differentiation of stem 
cells and mineralization of the extracellular matrix [200,202].  
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Mesenchymal stem cells (MSCs) are a multipotent stem cell population 
present in bone marrow, cartilage, and adipose tissue. They are easily differentiated 
into osteoblasts, chondrocytes, or adipocytes [90]. During MSCs differentiation, 
biological and mechanical cues induce specific pathways dictating whether the cell 
remains multipotent or differentiates into a specific cell type. Recently, Yeatts et al. 
demonstrated that the tubular perfusion system (TPS) bioreactor can promote 
differentiation of human MSCs (hMSCs) into osteoblasts via increased supply of 
convective oxygen and nutrient transport and mechanical stimuli from the shear flow 
of the media [203,204]. After in vitro culture, the scaffolds can form an aggregated 
constructed for in vivo implantation [205].  
In addition to dynamic culture, it is well known that hMSCs respond 
favorably towards several biochemical signals. Particularly, it has been reported that 
biopolymer scaffolds modified with growth factors (GFs) including fibroblast growth 
factor-2 (FGF-2), vascular endothelial growth factor (VEGF), or bone morphogenetic 
protein-2 (BMP-2) [206] could enhance in vivo bone growth. For example, VEGF, an 
angiogenic growth factor, has been used to enhance vascularization and integration of 
an implanted bone engineered scaffold seeded with MSCs [207,208]. Similarly, 
BMP-2 has been widely investigated for its role in enhancing in vivo bone growth 
and in vitro osteoblastic signaling [209–211], and is considered one of the main 
factors involved in ectopic bone formation [212].  
A locally sustained release of growth factors inside the 3D scaffold may 
provide an additional level of control. However, the production of reliable 
biopolymer microparticles for controlled release of GFs remains a challenge. 
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Recently, pharmacologically active microcarriers (PAMs) were proposed as transient 
scaffolds (or components of it) capable of controlled delivery of bioactive molecules 
[213,214]. Among all the biopolymers, Poly(D,L lactic-co-glycolic acid) PLGA 
received a strong interest for the development of bioactive microcarriers [215]. The 
use of supercritical fluids has been proposed for the production of biopolymer 
microspheres with an engineered size and distributions by an innovative technology, 
known as Supercritical Emulsion Extraction Continuous (SEE-C) layout [216]. 
Bioactive PLGA micro- and nano- carriers with mean diameters between 1 and 3 µm 
(±0.5 µm) loaded with active compounds [217], proteins [218], or bacteria [219] were 
successfully produced by SEE-C with a reliable process operations and are well 
characterized in terms of encapsulation efficiencies, release profiles of the bioactive 
compound, and good cell viability. 
We hypothesized that the temporally and spatially controlled release of 
hBMP2 or hVEGF under dynamic culture conditions would enhance osteogenic 
differentiation of hMSCs compared to no GF delivery in static conditions. To provide 
proof of concept, bioactive alginate scaffolds were loaded with hMSCs and PLGA -
encapsulated growth factor microparticles, specifically hVEGF and hBMP2 or a 
hVEGF-hBMP2 combination of both and cultured under shear stress in the TPS 
bioreactor. The system developed in this study could be used to deliver multiple 
bioactive growth factors and could find broad utility in many tissue engineering 




4.2 Materials and Methods 
4.2.1 PAM production by SEE-C technology 
Unloaded and GF-loaded microparticles were fabricated using previously 
established methods [220] utilizing a fixed water-oil-water emulsion ratio of 1:19:80. 
Briefly, GFs were dissolved into a 0.04% w/v human serum albumin (hSA) in poly-
vinyl alcohol (PVA) solution and added to the oily phase composed of ethyl acetate 
(EA) and PLGA at 10% w/w. The primary w1-o emulsion was obtained after 90 
seconds sonication with a digital ultrasonic probe at 50% of amplitude (Branson 
Ultrasonics Corporation, Danbury, CT). It was then immediately poured into a 0.6% 
w/w EA-saturated aqueous Tween 80 solution, which is used as outer water phase to 
form the secondary emulsion by a high-speed homogenizer (Silverson Machines Ltd., 
Waterside, Chesham Bucks, United Kingdom) for 6 min at 10°C in an ice bath with a 
stirring rate of 2800 rpm. The emulsions were then processed by SEE-C.  
As previously described, the SEE-C apparatus [220] consists of a packed column 
where gaseous and liquid phases are contacted counter-currently. Briefly, the 
separator is located downstream to recover the extracted oily phase solvent. SC-CO2 
and emulsion is delivered via high pressure diaphragm pump and high pressure piston 
pump, respectively. The emulsion is fed at the top and the SC-CO2 from the bottom 
of the column, which is packed with stainless steel packings (Pro-Pak, Scientific 
Development Company, State College, PA) and thermally insulated by ceramic 
cloths. During the processing, the oily droplets in the emulsion are continuously 
pumped into the high pressure packed tower and dried by carbon dioxide, resulting in 
solid polymer microspheres, which are recovered at the bottom of the tower. A 
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schematic representation of the SEE apparatus is described in Figure 4.1a). The 
operating pressure and temperature conditions in the high-pressure column were 8 
MPa and 38°C, respectively, with an SC-CO2 flow of 1.4 kg/h and an L/G ratio of 
0.1, as previously described [221]. At these conditions, the droplets in emulsions were 
converted into a PLGA microparticles water suspension in less than 5 min of 
residence time in the column, preventing any aggregation phenomena between 
particles. Each run allowed the recovery of 98% of the loaded biopolymer and 
assured an excellent batch-to-batch reproducibility. During the runs, the 
microparticles in water suspension are continuously collected at the bottom of the 
extraction column, washed with sterilized water by centrifugation, and then 
lyophilized. Additionally, they passed through a Pen/Strep (1% w/V) solution 




Figure 4.1 Schematic of SEE apparatus (a) and of tubular perfusion system 
(TPS) bioreactor setup (b). (a) The droplets in the w-o-w emulsion are continuously 
pumped into the a high pressure packed tower and dried by the carbon dioxide to 
produce the solid microspheres, which recovered at the bottom of the tower (adapted 
from Della Porta et al. 2011). (b) TPS bioreactor consists of media reservoir, growth 




4.2.2 Droplets and microspheres morphology & size distributions 
The droplets formed in the emulsion were observed using an optical microscope 
(Olympus, Tokyo, Japan) equipped with a phase contrast condenser. The shape and 
morphology of the microspheres were investigated by field emission-scanning 
electron microscopy (FE-SEM) (Carl Zeiss, Oberkochen, Germany). Then, the 
particle size distributions (PSD) were measured using a Mastersizer S apparatus 
(Malvern Instruments, Worcherstershire, United Kingdom), based on dynamic light 
scattering (DLS). For each analysis, 50 mg of particles in suspension were loaded into 
the instrument to monitor their sizes and deviations. Droplets and particle size are 
expressed as volume MS (mean size, µm) ± SD (standard deviation) of values 
collected.  
4.2.3 hSA and GFs loading and VEGF release study 
hSA was used in the microparticle production process as a GF stabilizer in the 
internal water phase of the double emulsion. The specific amount of hSA loaded into 
PLGA microparticles was determined by dissolving 10 mg of dried powder in 600 µL 
of acetonitrile and sonicating it in 1400 µL of water. The remaining undissolved 
PLGA was separated by centrifugation at 2000 rpm for 2 minutes. The resulting clear 
supernatant solution was directly analyzed at room temperature by high-performance 
liquid chromatography (HPLC) (Agilent Technologies Inc.). The amount of hSA in 
solution was calculated using of a calibration curve and then converting it into the 
effective loading in terms of amount (mg) of protein loaded into PLGA (g). Similarly, 
the amount of hVEGF loaded into PLGA microparticles was determined using an 
ELISA-based assay (PeproTech, Rocky Hill, NJ) and was calculated as the amount 
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(ug) of protein loaded in PLGA (g). The hBMP2 loading was assumed the same as 
hVEGF.  hVEGF release profiles were monitored in vitro using an ELISA-based 
assay. 20 mg of microparticles were suspended in 2 mL of Dulbecco's Modified 
Eagle Medium (DMEM) and placed in an incubator at 35°C and stirred continuously 
at 50 rpm. At fixed time intervals, the samples were centrifuged at 4000 rpm for 15 
minutes and the supernatant was completely removed and replaced with fresh media 
to maintain sink conditions. Released VEGF concentrations from collected samples 
were then measured with an ELISA assay (PeproTech, Rocky Hill, NJ). Release 
experiments were performed in triplicate and the proposed curves are the mean 
profiles obtained. 
4.2.4 hMSC Culture  
hMSCs (passage≤5) were purchased from Lonza (Walkersville, MD) and 
cultured in a growth media containing High Glucose DMEM with L-Glutamine 
(Gibco, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS, 
Invitrogen), 1% v/v penicillin/streptomycin (Gibco), and 0.1 mM nonessential amino 
acids (Invitrogen) following the manufacture’s protocol with a media change every 4 
days. Cells were stored at 37°C and 5% of CO2 and passaged every 6-7 days. The 
osteogenic media was formulated as previously [222] described by supplementing 
growth media with 100nM dexamethasone (Sigma, St. Louis, MO), 10mM β-
glycerophosphate, and 173 mM ascorbic acid (Sigma).  
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4.2.5 Ca-Alginate scaffold fabrication and encapsulation of cells and 
microparticles 
A 2% w/w alginate solution (Sigma Aldrich) was prepared by dissolving alginic 
sodium salt from brown algae (Sigma) in 0.15M NaCl (Sigma) and 0.025M HEPES 
(Sigma) in deionized water and sterilized via autoclave. hMSCs and GF-loaded 
PLGA microparticles were resuspended in HEPES buffer solution using sonification 
in ice water, poured into the sterile alginate solution, and thoroughly mixed. A 
syringe and 16 1/2G needle were used to create the 3D alginate hydrogel scaffolds by 
a slow drop wise suspension into a stirred a 0.1M calcium chloride solution (Sigma). 
Approximately, 72,500 hMSCs and 4.4 mg of PLGA microparticles were 
incorporated into each crosslinked alginate scaffold. The alginate scaffold mean 
diameter was of 0.3 (± 0.01) cm.  
4.2.6 Perfusion Bioreactor for Dynamic Environment 
A TPS bioreactor was used as a dynamic fluid conditioner (see Figure 4.1b). It 
consists of a tubular growth chamber and medium reservoir connected via a tubing 
circuit, as described in a previous work [222]. The medium’s flow was driven by an 
L/S Multichannel Pump System (Cole Parmer, Vernon Hills, IL) at 2 mL/min. The 
circuit consists of platinum-cured silicone tubing (Cole Parmer) and connects the 
growth chamber, which has high gas permeability to allow for easy exchange of 
carbon dioxide and oxygen. Each chamber’s internal volume was of 2.4 mL and 
loaded with 25 scaffolds (with a volume of 0.014 cm
3
) in order to reach a bioreactor 
packing value of 0.15 ratio (scaffolds/reactor volume). In total, 70 mL of osteogenic 
media was placed into separate media reservoirs to supply the growth chambers and 
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was changed every 3 days. The scaffolds were divided into four different groups, 
based on the GFs loaded microparticles (unloaded, hBMP2, hVEGF, or a 
combination of hBMP2 and hVEGF), where one growth chamber was utilized per 
timepoint per group. As a control, scaffolds were also placed into a static culturing 
environment with 2.13 mL of osteogenic media, to maintain the same media/scaffold 
ratio.  
4.2.7 Immunohistochemistry 
At each timepoint (1, 7, 14, and 21 days) alginate scaffolds were recovered 
from dynamic and static culture conditions. They were fixed in 4% paraformaldehyde 
(PFA) (Sigma) for 3 hours, followed by an overnight incubation in 0.1M sodium 
cacodylate/4% PFA (Sigma). The scaffolds were then dehydrated for histological 
processing in a series of ethanol dilutions (75%, 90%, 100%), embedded in paraffin 
(Fisher Scientific), and sectioned using a microtome (Lica) into 5-micron-thick 
sections. The samples were then deparaffinized in Citrisolv (Fisher Scientific) and 
rehydrated in ethanol.  
Osteoblastic differentiation was monitored using immunohistological staining 
of protein markers, including alkaline phosphatase (ALP), an early differentiation 
marker, and osteocalcin (OCN), a late differentiation marker. The samples underwent 
standard immunostaining protocol for antigen retrieval, and endogenous peroxidase 
and protein blocks. They were incubated for an hour with rabbit monoclonal ALP and 
mouse monoclonal OCN (Abcam, Cambridge, MA) antibodies, respectively, 
followed by broadband polyclonal biotinylated secondary antibody (Invitrogen). 
Antibody binding was visualized using peroxidase-conjugated DAB chromogen, 
 35 
 
which resulted in a brown stain. For the von Kossa staining, the sections were 
incubated in 2.5% (w/v) silver nitrate for 20 min under UV light, followed by 5% 
(w/v) sodium carbonate for 5 min, and 0.1% Nuclear Fast Red (Poly Scientific).  
4.2.8 Live/Dead assay 
Cell viability was assessed using a Live/Dead assay (Invitrogen) following 
standard protocols. Scaffolds were placed in 48-well plates and incubated in 2 mM 
ethidium homodimer and 4 mM calcein AM (Molecular Probes) for 30 min. Dead 
controls were incubated in 70% methanol (Sigma). Fluorescent images were then 
taken of the entire bead using a fluorescence microscope (Axiovert 40 CFL with filter 
set 23; Zeiss, Thornwood, NY) equipped with a digital camera (Diagnostic 
Instruments 11.2 Color Mosaic, Sterling Heights, MI).  
4.2.9 Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-
PCR) 
  To isolate mRNA from the cells, the scaffolds were homogenized and total 
RNA was isolated with Trizol Reagent (Invitrogen, Carlsbad, CA) following the 
supplier's protocol. Total RNA was quantified using a Nanodrop Spectrometer 
(Thermo Scientific, Wilmington, DE). Reverse Transcription was performed using 
TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA) 
following the supplier's protocol. qRT-PCR was performed using Taqman PCR 
Master Mix and Taqman Gene Expression Assays for ALP and OCN (Applied 
Biosystems). Quantification of target genes was performed relatively to the reference 
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GADPH gene. The mean minimal cycle threshold values (Ct) were calculated from 
triplet reactions. 
4.2.10 Statistical Analysis 
All samples were evaluated in triplicates. Data was analyzed using single-
factor analysis of variance followed by Tukey’s Multiple Comparison Test assuming 
normal data distribution with a confidence of 95% ( p<0.05). Mean values of 
triplicates and standard deviation error bars are reported on each figure as well as 
relevant statistical relationships. 
4.3 Results and Discussion  
4.3.1 PLGA microparticles: size, loading, and in vitro GFs release study 
  The encapsulation of two different GFs were considered: hBMP2, for its 
prominent role in the development of bone and cartilage and in inducing osteogenesis 
[223], and hVEGF, for its dual activity during angiogenesis and osteoblastic 
differentiation [224,225]. Briefly, double emulsions with a fixed PLGA content in the 
oily phase of 10% w/w and theoretical loading of 20 ug GF/g PLGA, with hSA as a 
stabilizer were prepared. Microparticles produced using SEE-C were measured to 
have MDs of 2.1 µm (± 0.6 µm). Examples of the results obtained are reported in 
Figure 4.2a), depicting optical microscopy (OM) and FE-SEM images of the 
emulsions. Three different microparticle batches were produced for the present study: 
1) unloaded particles (control), 2) hBMP2-loaded 3) hVEGF-loaded. The PSD curves 
of the three different microparticles are illustrated in Figure 4.2b).  In all cases, the 
hSA encapsulation efficiency was 80%, leading to the production of PLGA carriers 
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with a protein content of 2 mg hSA/g PLGA. The encapsulation efficiency value of 
80% was also confirmed for the GF loading, and was found to be 16 µg GF/g PLGA. 
An encapsulation efficiency of 80% exceeds those reported in literature [226,227], 
especially when ethyl acetate is used as oily phase solvent in a conventional emulsion 
evaporation technology. 
A release study of the encapsulated hVEGF into cell media was performed to 
evaluate the sustained release of growth factors from SEE-C fabricated 
microparticles. The release profile of GFs from 2.1μm PLGA microparticles into 
DMEM was monitored at 35°C and the experimental data are reported in Figure 
4.2c). A burst of about 20% of the GF was observed during the first day, followed by 
a more gradual and linear release over the following 16 days. The entire amount of 
encapsulated GF was released within 22 days.  
The drug release from PLGA can be described in two steps: the first one 
mainly reflects the diffusion controlled mass transfer of the drug accessible at the 
solid/media interface and the second step is due to the release of molecule 
encapsulated in the polymer layers enhanced by its bulk erosion via hydrolysis [228]. 
Assuming the spherical geometry of the system the diffusion coefficient as constant 
and the initial molecule concentration fixed, the diffusion controlled mass transfer 
equation can be written as (see Equation 1), where: Mt represent the amount of the 
released molecule at given time (t), M∞ is the maximum amount released, D is the 
diffusion coefficient of the molecule, and r the radius of the considered system: 
 




The hVEGF release data was modeled using Equation 1 to estimate the 
diffusion coefficient of the encapsulated hVEGF into microparticles considering a 
hypothetical media droplet with the same diameter as an alginate scaffold. In this 




/sec, and the resulting 
curve is reported in Figure 4.2c).  
Tanaka et al. [229] reported the diffusion characteristics of several substrates 
and proteins with different molecular weight, including fibrinogen (MW 34100 Da). 





/sec from Ca-alginate (2% w/w) scaffolds of 0.33 cm (±0.02) diameter 
at 30°, similar to the setup used in this work. The hVEGF used in this work has a 
MW of 38200 Da, which is similar in size to that of fibrinogen. Therefore the 
fibrinogen’s diffusion coefficient as reported by Tanaka et al. was used in equation 
(1) to simulate the release profile of free hVEGF from spherical Ca-alginate 
scaffolds. The resulting curve is seen in Figure 4.2c).  
  The extrapolated release profiles demonstrate that hVEGF encapsulated into 
PLGA microparticles result in a more delayed release profile compared to free 
hVEGF molecules from alginate scaffolds. The sustained release of hVEGF from 
PLGA microparticles can be considering the predominant step, whereas, the residual 
diffusion of free hVEGF into alginate can be neglected. Therefore, assuming that the 
2% alginate scaffold contains 98% water, we believe that the cells are directly 
exposed to and are affected by released GFs from PLGA microparticles inside the 







Figure 4.2 Microparticle characterizations. (a) Optical microscopy (left) and FE-
SEM (right) images of microparticle emulsion fabricated using SEE-C techniques of 
unloaded particles, hBMP2 loaded particles, and hVEGF-loaded particles. Each scale 
bar represents 20 mm. (b) Particle size distribution (PSD) curves of microparticles 
produced using SEE-C techniques. The size distribution curve of droplets in emulsion 
is shown as control (solid gray curve). Average size of PLGA microparticles was 
measured to be 2.3 mm in diameter. The three dashed curves, representing the 
unloaded, and two GF-loaded particles, are overlapping, confirming the high 
reproducibility of the SEE-C technology for the production of nanostructured 
microdevices. (c) hVEGF release curves from microparticles. Mathematically 
modeled curve of soluble VEGF diffusion out of a 3–mm diameter, 2% (w/w) Ca-
alginate scaffold (blue line). Mathematically modeled curve of VEGF release from 
PLGA microparticle into 3 mm diameter DMEM droplet (red line). Empirically 
released VEGF from PLGA microparticles into DMEM media (♦). Modeled data 
results indicate that soluble VEGF exhibits quickest diffusion from 2% alginate 
scaffold compared to VEGF encapsulated in PLGA microparticles. Collected VEGF 
release data demonstrates sustained release and correlates closely with modeled 
VEGF encapsulated PLGA curve.  
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Engineered bioactive scaffold characterization and TPS bioreactor conditions 
Alginate scaffolds with a mean diameter of 0.3 mm were loaded with hVEGF, 
hBMP-2, and a combination of hBMP2 and hVEGF mix of each per experimental 
group. 4.4mg of loaded PLGA microparticles were encapsulated in each scaffold, 
resulting in an average amount of 70 ng of hBMP2 or hVEGF, respectively, while 35 
ng of each GF were encapsulated into the scaffold in the hBMP2 with hVEGF 
experimental group. A schematic representation of the bioactive scaffold is shown in 
3a). A fluorescent viability stain was performed on the alginate scaffold at the end of 
the culture period as seen in Figure 4.3b), where green represents viable cells and red 
stains dead cells. The image displays high cell viability after encapsulation of the 
cells and microparticles in scaffolds. The internal structure of a freeze-fractured 
scaffold was also confirmed using FE-SEM at different magnifications, as seen in 
Figure 4.3). PLGA microparticles are uniformly distributed in the alginate matrix, 






Figure 4.3. Alginate encapsulation of microparticles and cells. (a) Schematic of 
cells (blue) and GF-loaded microparticles (green) in spherical alginate scaffold 
(pink). (b) Fluorescence staining of live (green) and dead (red) cells in alginate-
microparticle hydrogels on day 1 taken at 103 and2.53 (inset) magnification. The 
scale bar represents 200 mm. (c) FE-SEM images of hMSC- and microparticle-
encapsulated alginate scaffolds at 100x (top) and 1000x (bottom) magnification show 
homogenous distribution of PLGA microparticles in the alginate scaffold.  
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4.3.2 Immunoassay for cell differentiation monitoring 
  Alginate scaffolds were recovered from dynamic and static cultures at all 
timepoints for immunohistochemical analysis. ALP and OCN proteins were stained to 
monitor osteogenic differentiation in hMSCs during static and dynamic culture.  
During osteogenic differentiation, hMSCs will increase their deposition of minerals in 
the extracellular matrix (ECM). Therefore, von Kossa staining was used to study 
mineralization and calcification of the ECM, indicative of the stage of osteoblastic 
differentiation. Figures 4.4 depicts cross-sectional images of alginate scaffolds 
cultivated until day 14 and stained with von Kossa to observe the calcium deposition 
by hMSCs within the scaffolds. Mineralization, seen in dark brown/black, was 
minimal in static culture groups on day 7 (top panel), but increased in intensity by day 
14 (bottom panel). While mineralization was more prevalent in all dynamically 
cultured groups compared to static control, more homogeneous and intense deposition 
was especially observed in those exposed to sustained release of both hBMP2 and 
hVEGF on days 7 and 14.  







Figure 4.4. Mineralization of alginate scaffolds. Von Kossa histology staining of 
alginate scaffolds after 7 and 14 days of culture in the TPS bioreactor or static 
conditions. Calcium deposition is stained in brown/black and cells are stained in light 
pink. Darkest calcium staining is observed on day 14 for cells exposed to hBMP-2 
and a combination of hBMP2 and VEGF compared to empty and VEGF groups in 
both static and dynamic conditions, indicative of greatest calcium deposition in the 
extracellular matrix. All images were taken at 40x.  
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  To examine specific osteogenic protein expression, sections were stained for 
ALP and OCN (Figure 4.5). ALP is considered an early osteogenesis marker and is 
involved in making inorganic salts available for later calcification of the ECM. Its 
peak expression occurs between day 6 and 8 of culture [230], after which it decreases 
back to basal levels. The staining is more intense in the hBMP2, hBMP2 with 
hVEGF, and control groups but is not visually distinct from their respective static 
counterparts. Specifically, adding hVEGF seems to have the least beneficial effect on 
ALP expression, in both the static and dynamic conditions. Based on this ALP 
staining result, early differentiation protein expression can be affected by adding 
growth factors, specifically hBMP2, while exposure to hVEGF alone did not have 
favorable outcomes. Alternatively, OCN is a cellular structural protein in mature 
osteoblast produced between days 14 and 28 of osteogenic differentiation. The 
staining does not indicate noticeable differences in differentiation between the 
experimental groups. However, they have more intense staining than the empty 
control. Therefore, osteogenic protein production seems to be enhanced by all 
experimental groups containing growth factors, and further improved by dynamic 
flow.  More evident in the stains, however, is the size of the cells cultured in the GF 
supplemented dynamic conditions after 21 days, in which they are visibly larger than 
the cells in the static condition. We believe that this is due to the ability of the cells to 
expand and deposit more ECM in the degraded scaffolds by day 21 of the osteogenic 
differentiation culture when supplemented with GFs, resulting in a larger stained area 






Figure 4.5. Immunohistochemical staining of osteogenic proteins. Immunostaining 
of ALP on day 7 and OCN on day 14 indicate more intense staining on alginate 
scaffolds cultured in dynamic conditions compared to the static control. Greater 
staining was particular evident in cells exposed to hBMP2 and dynamic conditions 
compared to those exposed to hVEGF or no growth factor control. No qualitative 
difference was observed between staining of cells exposed to hBMP2 or both hBMP2 
and hVEGF.  
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4.3.3 Osteogenic Gene Expression 
  mRNA expression of ALP and OCN was also used to monitor osteogenic 
differentiation as seen in Figure 4.6. When dynamically cultured, ALP mRNA 
expression increased 10-fold on day 7 in groups supplemented with hBMP2 
compared to the remaining groups, which were not statistically different from one 
another (Figure 4.6a). However when cultured in static conditions, ALP mRNA 
expression was greatest in groups without growth factors and those exposed to the 
hBMP2 with hVEGF GFs on day 7 (Figure 4.6b). This could indicate that the burst 
release of growth factors does not initially affect early osteogenic differentiation, but 
instead is seen in later stages. For example, on day 21, delayed osteogenic markers 
OPN and OCN, indicated significantly higher expression in groups exposed to both 
hBMP2 and hVEGF GFs compared to the other groups (Figure 4.6c). Similarly, OPN 
mRNA expression was significantly higher in hBMP2 exposed groups, compared to 
the control or hVEGF group. In static culturing conditions, OCN mRNA expression 
was highest in groups exposed to hBMP2 and hBMP2 with hVEGF, with a 12.1 and 
14.1-fold change, respectively (Figure 4.6d). Therefore, groups exposed to hBMP2 
under dynamic culturing conditions performed similarly to when hBMP2 and hVEGF 
were added together to the TPS bioreactor. This may indicate that shear stress is able 
to support osteogenic differentiation of hMSCs during its later stages, as has been 






Figure 4.6. Gene expression of osteogenic markers. RT-qPCR for ALP and OCN 
mRNA expression from both static and dynamic conditions indicated statistically 
greater expression of ALP in dynamically cultured cells exposed to hBMP2. In static 
environments, while no statistical difference was observed between cells incubated 
with empty, hBMP2 loaded, or both GF-loaded microparticles, these groups 
expressed statistically greater amounts of ALP mRNA than the hVEGF group. OCN 
mRNA fold changes were also greater in the hBMP2 with hVEGF group when 
dynamically cultured, and in the hBMP2 and hBMP2 with hVEGF group in the static 
conditions. Groups with the same letters indicate no statistical difference between 
groups for that timepoint, with p<0.05.  
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Overall, hBMP2 and the combination of hBMP2 and hVEGF delivery resulted 
in greater osteogenic differentiation, compared to control and hVEGF additions alone.  
ALP mRNA expression was most enhanced when cultured in dynamic conditions and 
supplemented with hBMP2, resulting in a 10.3 fold increase on day 7 compared to 
day 1. In static culture, the addition of growth factors did not seem to improve ALP 
mRNA expression compared to the control, demonstrating that hBMP2 and hVEGF 
may influence later osteogenic differentiation pathways. On the other hand, dynamic 
culture largely enhanced differentiation compared to static culture, observed in both 
early and late osteogenic marker mRNA expressions. Although we hypothesized that 
the addition of both hBMP2 and hVEGF would individually enhance osteogenesis 
and therefore amplify the effect when used in tandem, the results indicate that hBMP2 
may have a dominant effect on hMSCs over hVEGF, especially when dynamically 
cultured. The addition of hVEGF had minimal effects on the hMSC culture compared 
to the non-growth factor supplemented control. Therefore, we believe that the dual 
application of mechanical stimulation through fluid flow as well as the addition of 
osteogenic growth factors results in the greatest enhancement of osteogenesis in 
hMSCs. 
  The delivery of BMP2 and VEGF for bone tissue engineering has been 
previously explored in static conditions [59,65,225,233]  with many advocating for 
their synergistic effects on osteogenesis [59,234]. However, several have pointed out 
the hindering effect of VEGF in vitro [235], although it can be beneficial when 
utilized in vivo.  Specifically, high concentrations of VEGF have been found to lead 
to stem cell differentiation towards the endothelial lineage, decreasing the amount of 
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cells available to undergo osteogenic differentiation [236]. Others have investigated a 
variety of different GF ratios, but have had similar results, where BMP2 has a more 
prominent effect on osteogenic differentiation than VEGF [225]. Lastly, great efforts 
have been spent on investigating the importance of temporal control of growth factor 
release. For example, different kinetic rates of GF release have been found to enhance 
regeneration of critical bone defects [237], where BMP2 enhanced bone  formation 
and a combination of BMP2 and VEGF increased bone bridging and union of defect 
compared to BMP2 alone. These studies indicate a need to fully understand the 
interplay between BMP2 and VEGF in bone regenerative applications.  
4.4 Conclusion 
  In this work, PLGA microparticles were utilized as delivery vehicles for 
hBMP2 and hVEGF to enhance the osteogenic differentiation of hMSCs while 
dynamically cultured in the TPS bioreactor.  The histological staining as well as gene 
expression assays confirmed that this dual application of biochemical and mechanical 
stimulation promoted osteoblastic differentiation of hMSCs compared to static 
conditions. In addition, the sustained release of growth factors to 3D encapsulated 
cells resulted in improved osteogenic differentiation, therefore indicating that SEE-C 
technology is a promising tool in the field of tissue engineering and regenerative 
medicine. These microparticle devices can be included in complex 3D scaffolds with 
cells onboard for local signal delivery. Further confirming the results, von Kossa 
staining revealed that hBMP2 and hVEGF mix released in alginate scaffolds has a 
great influence of the on hMSC differentiation into osteoblasts. Therefore, the 
combination of hBMP2 and dynamic culture in the TPS bioreactor allows for 
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Chapter 5:  Tunable Osteogenic Differentiation of hMSCs in 




  Mesenchymal stem cells (MSCs) are multipotent cells that have been studied 
in a variety of bone tissue engineering applications. A combination of specific 
mechanical and biochemical stimuli commit MSCs to differentiate along an 
osteogenic lineage into osteoblasts and osteocytes, among the main cell types in bone 
tissue [238]. In tissue engineering, MSCs are often paired with three-dimensional 
synthetic or organic scaffolds and cultured for the development of bone tissues. When 
dynamically cultured, these cell constructs have demonstrated advanced tissue 
formation [197,239–242].Therefore, these systems have promising applications in 
treating bone trauma or defects in clinical settings [139,243]. 
In this work, human MSCs (hMSCs) are encapsulated in alginate scaffolds 
and studied in vitro under dynamic culture conditions within a bioreactor system. 3D 
static culture techniques are often inadequate in delivering essential nutrients and 
oxygen through simple diffusion [196,244]. Various dynamic bioreactor designs have 
since been conceived to solve these issues by providing increased oxygen and nutrient 
supply [245]. The tubular perfusion system (TPS) bioreactor, previously developed 
by Yeatts et. al., utilizes a peristaltic pump to drive media throughout a growth 
chamber that houses 3D alginate scaffolds [240,246,247]. A media reservoir provides 
fresh nutrients for the tissue and collects cellular wastes as media perfuses throughout 
the system. The dynamic culture environment of the TPS bioreactor has several 
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advantages over alternative static methods; engineering three dimensional structures 
facilitates efficient penetration of nutrients and oxygen into the scaffolds through 
fluid perfusion. This benefit encourages cell growth and is essential for homogenous 
construct formation by preventing hypoxia and malnutrition in developing tissues 
[247].  
Further, the TPS bioreactor enhances osteogenic differentiation of hMSCs 
encapsulated in alginate scaffolds. Fluid shear stress produced by a perfusion 
bioreactor activates certain biomechanochemical pathways that upregulate key 
osteogenic differentiation markers such as alkaline phosphatase (ALP), osteocalcin 
(OCN), and osteopontin (OPN), as well as growth factors, like bone morphogenetic 
protein-2 (BMP-2) [248–250]. Growth factor concentrations and permutations 
dominate control of the osteogenic enhancement pathways and are important in 
paracrine signal regulation in tissue formation [251,252].  
Previously, studies have explored the effects of bioreactor flow patterns on 
osteogenic differentiation of encapsulated stem cells [253]. For example, parallel flow 
resulted in retained proliferation and hMSC progenicity by reinforcing ECM 
characteristics, while transverse flow enhanced osteogenic activity after 14 days. 
These results are attributed to the increased shear stress stimulation during transverse 
flow compared to parallel flow. Similarly, Du et al. described oscillatory flow that 
also proceeded to enhance osteogenic differentiation in a uniform manner, compared 
to unidirectional flow [254]. 
Several studies have indirectly studied growth factor release in perfusion bioreactors 
[255–258], yet the effect of flow in an axial growth chamber on paracrine signaling 
 54 
 
molecule expression in subpopulations has not been fully described. Understanding a 
complex dynamic culturing system, where one population may affect another through 
paracrine signaling, could be greatly useful in coculture setups where a supporting 
cell population is necessary for the survival and function of a primary cell population 
[259–262].  
Here, we investigate the variances in osteogenic differentiation between 
encapsulated-hMSCs that lie at the proximal (inlet) end of the axial growth chamber 
compared to those that lie at the distal end (outlet) of the tubular growth chamber in 
the TPS bioreactor. We hypothesize that these two regions may experience 
differences in biochemical (mass transport of growth factors, nutrient and oxygen 
delivery) factors that govern and enhance osteogenic differentiation. This work 
promotes greater understanding of axial growth chamber culture, how well-
established parameters of osteogenic differentiation can be manipulated for advanced 
tissue development. Furthermore, this work suggests the ability to control localized 
microenvironments in a dynamic culturing system such as the TPS bioreactor, which 
would be advantageous in engineering heterogeneous or co-culture tissue constructs.  
5.2 Materials and Methods 
5.2.1 Human Mesenchymal Stem Cell Culture  
Human mesenchymal stem cells (hMSCs) (passage≤5) were purchased from 
Lonza (Walkersville, MD) and cultured in a growth media containing High Glucose 
DMEM with L-Glutamine (Gibco, Carlsbad, CA), supplemented with 10% fetal 
bovine serum (FBS, Invitrogen), 1% v/v penicillin/streptomycin (Gibco), and 0.1 mM 
nonessential amino acids (Invitrogen) following the manufacture’s protocol with a 
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media change every 4 days. Cells were stored at 37°C and 5% of CO2 and passaged 
every 6-7 days. The osteogenic media was formulated as previously described29 by 
supplementing growth media with 100nM dexamethasone (Sigma, St. Louis, MO), 
10mM β-glycerophosphate, and 173 μM ascorbic acid (Sigma). 
5.2.2 Cell and Growth Factor Encapsulation 
Human recombinant BMP-2 (Sigma) was resuspended in water as described 
in the manufacturer’s protocol. For cell experiments, hMSCs were mixed into 2% w/v 
alginate (Sigma) solution and used to make alginate scaffolds by adding the mixture 
dropwise into a suspension of 0.1M calcium chloride (Sigma) (100,000cells/scaffold), 
Similar, 6mg of BMP-2 was encapsulated in acellular alginate scaffolds, resulting in a 
BMP-2 concentration of 60ng/scaffold. 
5.2.3 TPS Bioreactor Assembly 
Alginate scaffolds were divided into experimental (dynamic culture) and control 
(static culture) groups. The dynamic group was further separated into “A” and “B” 
groups based on their culture chamber location in the TPS bioreactor. The bioreactor 
was set-up as described previously (Yeatts et al. 2011). Scaffolds were loaded into 
tubular growth chambers (10 scaffolds per chamber). Medium flow was driven by an 
L/S Multichannel Pump System (Cole Parmer, Vernon Hills, IL) at a flow rate of 3 
mL/min. Static scaffolds were cultured in six-well plates (10 scaffolds per well). The 
medium was changed every two days. At each timepoint, hMSCs were isolated from 
alginate scaffolds by dissolution in ethylenediaminetetraacetic acid (EDTA) for 30 
 56 
 
min at 37°C. A cell pellet was formed by centrifugation and used for subsequent 
analyses. 
5.2.3.1 Unidirectional Flow 
When unidirectional flow was used in the dynamic culture, 10 hMSC-loaded 
scaffolds were equally separated into two chambers, A and B (proximal and distal in 
relation to the source of the flow, respectively) (Figure 5.1b). After 1, 7, and 21 days 
of culture, all scaffolds were removed from the chamber (first 5 scaffolds categorized 
as ‘inlet’ and the latter 5 as ‘outlet’), and processed for further analysis.   
5.2.3.2 Alternating Flow  
To determine the effect of directional flow on osteogenic differentiation of 
hMSCs, the flow was alternated between clockwise (CW) and counterclockwise 
(CCW) every 24 hours for 7 days. Culture chambers were categorized as ‘A’ and ‘B’, 
despite the direction of the flow (Figure 5.1c). On day 1 and 7, 5 scaffolds were 
removed from each chamber for further analysis. 
5.2.3.3 Growth Factor-Supplemented Flow 
To supplement the culture with control-released growth factor, an additional 
growth chamber was placed preceding chamber A and B (Figure 5.1d). It contained 
20 BMP-2 encapsulated alginate scaffolds. These were fabricated similar to the cell-
encapsulation protocol. BMP-2 was mixed into 2% alginate solution, added dropwise 
into a solution of 0.1 M CaCl2, and stirred for 10 min using a stir bar. Then scaffolds 
were placed into a growth chamber in the TPS bioreactor, where they would release 
their contents into the media to travel downstream towards chambers A and B.  At 







Figure 5.1. TPS Bioreactor Assembly. A) The TPS bioreactor consists of a 
peristaltic pump, which continuously pumps media through a growth chamber from a 
media reservoir. B) Two-chamber setup with uni-directional flow. Scaffolds cultured 
in the proximal and distal chambers are labeled in green and red, respectively. C) 
Three-chamber setup with uni-directional flow. BMP-2- encapsulated scaffolds 
(green) release the growth factor towards proximal and distal culture chambers 
(purple and red).   
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5.2.4 Computational Fluid Dynamics Modeling of Fluid Shear Stress 
SolidWorks (Waltham, MA) was used to create a 3D model of the TPS 
bioreactor growth chamber. A cylindrical tube 6.35 mm in diameter was fixed in a 
motion study, and 20 spheres (3.41 mm diameter – based on averaged experimental 
data, not shown) were dropped in gravity to represent in vitro loading and culturing 
conditions of alginate bead scaffolds. Contact points were fixed in place, and the 
model exported to SolidWorks Flow Simulation.   Using an inlet flow rate (3 
mL/min), velocity data was generated using the “Point Parameters” function of 
SolidWorks Flow Simulation and analyzed in MATLAB using numerical 
approximations of Navier-Stokes Equations and the Cauchy Stress Tensor.    
5.2.5 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
5 scaffolds per group were used to isolate total RNA from hMSCs using the 
RNeasy Plus Mini Kit (Qiagen, Frederick, MD) following standard protocols. 
Isolated RNA was then reverse transcribed to cDNA using a High Capacity cDNA 
Archive Kit (Life Technologies). Quantitative RT-PCR was performed by combining 
the cDNA solution with a Universal Master Mix (Life Technologies), as well as 
oligonucleotide primers and Taqman probes for ALP and OCN, and the endogenous 
gene control glyceraldehyde 3 phosphate dehydrogenase (GAPDH) (Life 
Technologies). The reaction was performed using a 7900HT real-time PCR System 
(Applied Biosystems) at thermal conditions of 2 min at 50°C, 10 min at 95°C, 40 
cycles of 15 s at 95°C, and 1 min at 60°C. The relative gene expression level of each 
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target gene was then normalized to the mean of day 1 GAPDH expression in each 
group. Fold change was calculated using the ΔΔCT relative comparative method as 
described previously 17. Samples were completed in technical triplicates and standard 
deviations are reported (n=3). 
 5.2.6 Histology 
To visualize later stages of osteogenesis via the mineralization of extracellular 
matrix (ECM) and deposition of calcium, scaffolds were recovered from static and 
dynamic conditions and fixed in 4% paraformaldehyde (PFA) for 3 hours, followed 
by an overnight incubation of 0.1M sodium cacodylate/4% PFA (Sigma). Next, the 
scaffolds were dehydrated in a series of ethanol dilutions and embedded in paraffin 
wax. Samples were sectioned into 5 um slices using a microtome (Lica). For the von 
Kossa staining, the sections were incubated in 2.5% (w/v) silver nitrate for 20 min 
under UV light, followed by 5% (w/v) sodium carbonate for 5 min, and 0.1% Nuclear 
Fast Red (Poly Scientific). Stained samples were visualized under brightfield 
microscopy (Zeiss, Germany). 
5.2.7 Quantitative ALP Assay 
ALP activity in hMSCs is an indicator of early osteoblastic differentiation and 
their commitment towards the osteoblastic lineage. Expression of ALP protein was 
quantified using media extracts on timepoint days. In the presence of an alkaline 
buffer, ALP hydrolyzes phosphate esters, producing organic radicals and inorganic 
phosphates. Utilizing the phosphate assay kit (Abcam), media extract was mixed with 
 60 
 
a fluorescently tagged phosphate group, which when cleaved results in an intense 
fluorescent signal. 
5.2.8 BMP-2 Release Study 
BMP-2 release profiles were monitored in vitro using a BMP-2 specific 
enzyme-linked immunosorbent assay (ELISA) (Sigma). The growth factor was 
encapsulated into alginate scaffolds are described above and placed into serum-
containing Dulbecco’s Modified Eagle Medium (DMEM) and placed in a shaker at 
37°C. At fixed time intervals, the media was removed and flash frozen in liquid 
nitrogen, while the scaffolds were disregarded. The media was evaluated for BMP-2 
content and absorbencies read using a plate reader at 450nm. Standard curves were 
made using human recombinant BMP-2, while serum-containing media was used as a 
baseline. 
5.2.9 Statistical Analysis 
Each analysis was performed in triplicate (n=3). Statistical significance was 
determined by one-way analysis of variance and Tukey’s multiple-comparison test. A 
confidence interval of 95% (α = 0.05) was used for all analyses.  Mean values of 
triplicates and standard deviation error bars are reported on each figure as well as 




5.3.1 Characterization of Axial Position on hMSC Response  
First, osteogenic differentiation in cells cultured under unidirectional flow 
(Figure 5.1B) was analyzed using gene expression and histological staining. qPCR 
analysis showed expression of osteogenic markers such as alkaline phosphatase, an 
early differentiation marker, was upregulated on day 7 in cells cultured in chamber B 
compared to those cultured chamber A (Figure 5.2A). Similarly, mRNA coding for 
osteocalcin, a late osteogenic marker, was also increased 1.5-fold by day 21 in 
chamber B, while those in chamber A experienced 0.5-fold decrease compared to day 
1 (Figure 5.2B). However, BMP-2 gene expression showed significant increase after 
21 days, albeit no statistical difference between groups (Figure 5.2C). The trend in 
gene expression was further confirmed through histology staining to visualize 
calcification of the extracellular matrix using Von Kossa. The microscopy images 
indicate that there is greater mineralization of the ECM (stained in black) by day 7, in 
surrounding areas of cells in chamber B compared to those in chamber A (Figure 
5.2B). However, calcification is not visibly different by day 21 between the two 
groups.  
Second, we investigated whether we could mitigate the effects seen in the 
unidirectional flow by alternating between CW and CCW every 24 hours. 
Specifically, ALP mRNA expression remained similar to day 7 for cells in chambers 
A and B (Figure 5.3A). However, we analyzed the concentrations of BMP-2, an 
important osteogenic growth factor released during differentiation, and found that 
these were not statistically different between media surrounding cells in the chambers 
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A and B (Figure 5.3C). The BMP-2 concentration increased in all groups and was 
statistically different by day 7 compared to day 1.  Increased differentiation was 
further confirmed with Von Kossa staining for mineralization on day 1 and day 7 
(Figure 5.3B). Calcium deposition was visible in both groups by day 7 with no 






Figure 5.2. Unidirectional Flow Promotes Osteogenic Differentiation in 
Downstream hMSCs.  A) Increased expression of early osteogenic marker ALP was 
observed in hMSCs cultured in distal scaffolds compared to those in the proximal 
chamber. B) By day 21, there was significantly greater expression of OCN, a late 
stage osteogenic marker, in the distal group, compared to the proximal group. C) Von 
Kossa histology staining shows great calcification (black) in distal cells on Day 7 
compared to proximal cells, however no noticeable difference by Day 21. Scale bar 






Figure 5.3. Alternating Flow Pattern Mitigates Variances in hMSC Osteogenic 
Differentiation. A) ELISA detection of BMP-2, a marker of osteogenic 
differentiation, indicated no statistical differences between hMSCs cultured in the 
proximal or distal chambers.  B) Von Kossa staining on Day 7 indicated no 
qualitative differences in staining intensity of mineralized ECM (black) between 
hMSCs (pink) cultured in the distal or proximal chambers. C) mRNA expression of 
ALP showed significant increase over 7 days of dynamic culture (4 and 5.3-fold), but 
not significant differences between cells cultured in chamber A or B.   
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5.3.2 Consideration of Shear Effects 
We used computational fluid dynamic (CFD) analysis to confirm that the flow 
rate in chamber A was not different from that in chamber B during unidirectional 
flow and therefore was not the leading cause in osteogenic differences seen during 
unidirectional flow. MATLAB approximation for finite shear stress elements 
supported the theory that alginate scaffolds in chamber A experienced on average 
(across all three simulation builds) 15.6 ± 1.8 mPa of fluid shear stress while 
scaffolds in B experienced 15.1 ± 3.5 mPa, with no statistical difference between 
groups. 
5.3.3 Consideration of Paracrine Signaling Effects 
Results from the unidirectional flow experiment indicated the presence of 
paracrine differences between cells cultured in chamber A and B. Therefore, to 
demonstrate the signaling behavior between cultured groups, we introduced an 
additional growth-factor releasing element.   
Here, we determined the effect of exogenous growth factor delivery in a 
unidirectional system on osteogenic differentiation of hMSC. We analyzed gene 
expression of ALP and BMP-2 in dynamic and static conditions (Figures 5.5A-D). 
Both ALP and BMP-2 expression fold change were not statistically different between 
groups in chambers A and B on day 7 when cultured in the TPS bioreactor (Figures 
5.5A&C). However, both increased drastically from day 1 values (15-fold and 18-
fold, respectively). In addition, BMP-2 supplemented static cultures exhibited 
statistically different and greater expressions of ALP and BMP-2 mRNA compared to 
static control (no added growth factor) (Figures 5.5B&D). ALP production was 
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further quantified using an ALP fluorometric assay (Figure 5.4E). Media taken from 
all three chambers (BMP-2, A, and B) as well as the media reservoir showed no 
statistically different ALP protein concentration on day 7.  In addition, an ELISA 
assay was used to model the release of encapsulated BMP-2 from alginate scaffolds 
(Figure 5.4F). The release profile indicates a relatively slow release of 10% over the 
initial 40 minutes, followed by a burst release of 40% by 60 minutes. After 2 hours, 






Figure 5.4. Computational Fluid Dynamic Modeling. A) Velocity heat map of 
unidirectional flow in growth chamber, modeled in SolidWorks. Distribution of 
velocities are visible on the surface of scaffolds, ranging from 0-0.006 m/s, but no 
distinguishable difference is visible between scaffolds in part A compared to part B. 
B) Average shear stress calculated per scaffold, based on average velocity. C) 
Average shear stress on scaffolds from chamber A and B are not statistically different 
and display similar variability. D-F) SolidWorks model and histograms of shear stress 
distribution of individual scaffolds in growth chamber. Both entrance scaffolds and 
chamber A and B experience shear stresses below 0.05 Pa, with very small pockets of 






Figure 5.5. Influence of Exogenous BMP-2 Supplemented Flow. A) ALP gene 
expression fold change in dynamic culture was not statistically different between 
chambers A and B on day 7, but showed 15-fold increase over 7 days. B) ALP gene 
expression for cells cultured in static, with or without added BMP-2. The latter 
expressed significantly higher levels of ALP mRNA. C) BMP-2 expression in 
dynamically cultured cells.  No statistical difference was observed between groups on 
day 7, but both were significantly increased compared to day 1 levels. D) BMP-2 
gene expression in statically cultured cells was significantly enhanced with BMP-2 
supplements on Day 7. E) ALP production was quantified using an ALP fluorometric 
assay. There was no statistical difference in ALP protein detected in media samples 
on day 7. F) The release profile of BMP-2 encapsulated in 3-mm alginate scaffolds 
indicates a slow release of 10% over the initial 40 minutes, followed by a burst 
release of 40% by 60 minutes. After 2 hours, all BMP-2 has presumably been 




Bioreactors have been widely utilized in tissue engineering applications, 
especially for bone regeneration due to their ability to provide a dynamic culturing 
environment, a preferred condition during osteogenic differentiation of hMSCs 
[49,263–265]. Specifically, the TPS bioreactor increases oxygen and nutrient supply 
to cells encapsulated in hydrogel scaffolds, but also applies fluid flow forces that lead 
to molecular changes in cells as surface receptors trigger molecular pathways 
downstream [240]. Although their overarching effects on hMSCs have been 
previously investigated, the role of axial position within a perfusion bioreactor, like 
the TPS, on cell response has not yet been explored. In particular, we hypothesized 
that these variations in shear stress and/or paracrine signaling affect the genotype of 
downstream cells. This unique feature allows us to culture distinct populations of 
differentiating hMSCs for a variety of different tissue engineering applications where 
a range of differentiating cells are needed.  
This series of experiments has investigated the effect of axial position in the 
TPS bioreactor on the osteogenic differentiation of hMSCs. Empirical experiments 
using the linear growth chamber demonstrated that differences in differentiation exist 
between cells cultured along the length of the growth chamber. Specifically, cells 
cultured downstream (in chamber B) displayed enhanced expression of key 
osteogenic markers compared to those upstream (in chamber A). We hypothesized 
that these variations could be attributed to either 1) deviations in shear stress on the 
surface of dynamically cultured scaffolds, and/or 2) the release of endogenous growth 
factors and cytokines from one subpopulation of cells to another.  
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To examine if we could mitigate the osteogenic differences seen during 
unidirectional flow, we alternated between clockwise and counterclockwise flow 
every 24 hours. By oscillating the flow between CCW and CW, the osteogenic 
differentiation occurred at the same pace between cells in chambers A and B, as 
shown by endogenous BMP-2 production, ALP mRNA expression, and Von Kossa 
staining for calcium deposition on day 7. This flow pattern further confirmed the 
importance of directional flow in osteogenesis using any axial perfusion bioreactors 
[266–268]. 
We utilized computational fluid dynamic modeling to visualize the shear 
stress exhibited on alginate scaffolds. This analysis would verify the role of 
mechanical stimulation in the TPS bioreactor. Growth chamber simulations 
determined that there were no significant differences in applied fluid shear stress on 
scaffolds downstream of the inlet flow (Figure 5.1E). Therefore, we investigated 
paracrine signals as an overarching effect to biochemically induce osteogenic 
differentiation throughout the alginate scaffold. This theory has also been described 
by Kim, et al. in which hMSCs’ osteogenic differentiation was upregulated using 
transverse bioreactor flow compared to parallel flow [269]. In this model, they found 
the shear stress on the surface of the constructs to be 5.5 x 10-4 Pa.  
The CFD model confirmed that shear forces are not responsible for the 
osteogenic differences observed during unidirectional flow. Therefore, we 
hypothesized that paracrine signaling may be the driving force behind cellular 
behavioral discrepancies seen previously. We attempt to replicate this phenomenon 
by delivering exogenous BMP-2, an important growth factor released during 
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osteogenic differentiation, for an extended period. The sustained release resulted in a 
positive feedback mechanism [270,271], in which exogenous BMP-2 triggered 
expression of endogenous BMP-2, further enhancing osteogenic differentiation on 
day 7. More noticeably, however, was the fold changes of ALP expression on day 7 
with and without supplemented BMP-2. Cells cultured in chamber A experienced a 
1.9-fold change in ALP expression from day 1 to day 7 (Figure 5.2A). Yet the 
expression change was almost 20-fold when supplemented with BMP-2 (Figure 
5.4A). This indicates the synergistic role that dynamic culture and exogenous growth 
factors play on early osteogenic differentiation of hMSCs.  
Furthermore, an analysis of the circulating exogenous growth factor on 
cultured cells within the TPS bioreactor provided additional insight into its efficacy. 
With an average length of 5 cm each, growth chambers A and B were connected via a 
short, meshed connector, which allowed for the flow of media and growth factors, but 
prevented alginate scaffolds from leaving their respective growth chambers. The TPS 
bioreactor flow was set at 3mL/min, resulting in a media retention time of 31.7 
seconds per chamber. Therefore, any soluble growth factors and cytokines released 
by the cells, could be carried with the flow towards cells further downstream in 
chamber B and exit both growth chambers in about a minute. Such timescale is vital 
to consider due to the short half-life of many proteins. For example, the half-life of 
BMP-2 in vivo has been found to be 7-16 minutes systemically [272] and an hour in 
in vitro culture conditions [273]. At this degradation rate, BMP-2 and other growth 
factors should have sufficient time to circulate through the TPS bioreactor system, 
while remaining biologically active, to affect cells downstream.  Specifically, BMP-2 
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regulates the proliferation and osteogenic differentiation of precursor cell lines into 
osteoblasts and osteocytes [147]. Therefore, with the aid of a closed circuit setup of 
the bioreactor, growth factors are able to continue circulating the system, moving 
from the media reservoir back into chamber A. In conjunction with the gradual 
release of exogenous BMP-2 from alginate scaffolds, the encapsulated cells are fully 
exposed to the growth factor for several hours during the dynamic culture. Despite the 
burst release of BMP-2, the effect on cells is significant as shown by both mRNA and 
protein expressions (Figure 5.4).  
Finally, these experiments have demonstrated the overarching role of 
paracrine signaling in axial chamber culture, specifically their role in osteogenic 
differentiation. It plays a key role in promoting osteogenic differentiation within a 
subpopulation of cells for a bone tissue engineered construct. 
5.5 Conclusion 
While perfusion culturing systems like the TPS bioreactor have been shown to 
improve differentiation of hMSCs into osteoblasts, the ability to control the process 
has not been investigated. By utilizing the spatial control provided by the TPS 
bioreactor and the cell’s intrinsic expression of growth factors and cytokines, we have 
been able to show regulation of hMSCs’ osteogenic differentiation. Such uniaxial 
culturing system would be immensely useful in regenerative medicine applications 
where a coculture of interdependent, yet distinct cell populations is necessary. Such 
organizational structure is seen in the three defined zonal populations that make up 
cartilage [274]or in the coupled interaction of smooth muscle cells and endothelial 
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cells during angiogenesis and vascularization [275], where a coculture system of cells 
interact via paracrine signaling is vital. 
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 Critically sized bone defects affect an average of 1.5 million Americans per 
year and command a market of more than 1 billion dollars in repair and regenerative 
therapies [1]. The current therapies are based on various types of autografts, 
allografts, or synthetic bone grafts. Unfortunately, current treatments can result in 
host rejection, improper vascularization, incomplete healing, or life threatening 
complications from surgery. New efforts have focused on bone grafts generated using 
tissue engineering techniques. Many groups have utilized bone marrow derived 
human mesenchymal stem cells (hMSCs) to grow tissue grafts on a variety of natural 
and synthetic beads [276–278]. hMSCs have the ability to differentiate quickly into 
osteogenic cells and have been characterized as strong immunomodulators and 
paracrine activity regulators, which could lead to robust in vivo function post 
implantation [279].  
 Initially, static conditions were used to culture bone tissue grafts 
[196,280,281]. However, these fail to deliver adequate nutrient supply and remove 
waste products, and can lead to poor tissue formation, necrosis, and incorrect cell 
migration [196,282]. Therefore, the need for a dynamic culture environment is 
imperative for the in vitro formation of functional bone grafts. Bioreactors provide 
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increased control over environmental parameters such as media flow and oxygen 
distribution. Perfusion bioreactors, by enabling the continuous and circular flow of 
media and oxygen through the perfusion chamber, have demonstrated improved mass 
transport inside scaffolds and upregulation of important osteoblastic markers 
[201,240,241,245,254]. Such bioreactors mimic in vivo environments, where human 
bone tissue is subjected to two mechanical stimuli during development or 
regeneration: fluid shear strain and physical tissue stress [283]. 
Notably, our group has shown that the tubular perfusion system (TPS) 
bioreactor, which comprises a perfusion chamber where the cells and scaffolds are 
cultured, a medium reservoir, a tubing circuit, and a peristaltic pump, maintains cell 
viability at the center of grafts and enhances osteogenic differentiation of hMSCs 
compared to static culture conditions [222,284,285]. Computational modeling of 
steady-state oxygen concentrations throughout an alginate bead cultured under static 
and dynamic conditions illustrated that oxygen concentration fell to 0.03 mM and 
0.15 mM oxygen, respectively, suggesting that greater oxygen supply to encapsulated 
cells will maintain their viability and function [284]. Additionally, simplified 
COMSOL modeling of the fluid flow pattern in the TPS bioreactor growth chamber 
indicated velocities as high as 3.5 cm/s given a 3mL/min flow rate [284]. This shear 
stress is applied to the surface of the alginate bead, triggering several 
mechanotransduction receptors on the cell membrane surface of encapsulated hMSCs, 
ultimately leading to augmented osteogenic differentiation [231]. Furthermore, we 
have investigated such mechanical stimulation within the local environment of the 
alginate bead after 2-3 weeks of dynamic culture and discovered that the effects of 
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shear stress on the surface, while localized to a volume close to the surface, 
encourage the release of paracrine factors, that in turn, affect the response of the cells 
in the core of the bead [250]. Leveraging the dynamic culture of these versatile 
scaffolds, we aggregated the small alginate beads into a larger construct and 
demonstrated continued viability and function of the encapsulated cells [205]. More 
importantly, TPS bioreactor cultured cells were able to induce increased bone 
formation after implantation into a rat critical sized bone defect [286].  These positive 
outcomes allow us to further build upon our system, especially in the application of 
fabricating high volume tissue constructs.     
 Multiple studies have demonstrated positive effects of dynamic perfusion 
bioreactor culture on osteogenesis for bone tissue engineered bone grafts [240,287–
291]. To date, tissue engineered bone constructs cultured in dynamic conditions using 
the indirect perfusion bioreactors have been fabricated up to a volume of 10.7 cm
3
 
[287,288]. However, many systems are currently limited by the size of the culture 
chamber and inefficient supply of oxygen and nutrients to critical defect sized grafts. 
The goal of this study is to engineer a scale-up of a 1 inch bone graft to a full-size, 
superior portion of an adult human femur (200 cm
3
). We successfully demonstrate 
that the TPS bioreactor system can support cell viability and function throughout the 
entire engineered tissue. This work signifies a major step in tissue engineering by 
creating high volume bone constructs that could help regenerate entire bones. Further, 
the scalability of the TPS bioreactor could expedite fabrication of other whole organs 
and tissues that would otherwise require multiple systems and strategies. To our 
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knowledge, this is the first time a tissue-engineered bone construct of such size has 
been fabricated in the laboratory.  
6.2 Materials and Methods 
6.2.1 Human Mesenchymal Stem Cell Culture 
 Bone marrow-derived human mesenchymal stem cells (hMSCs) (passage ≤ 5) 
for use in the 1-inch bone construct were purchased from Lonza (Walkersville, MD) 
and cultured in a growth media containing High Glucose DMEM with L-Glutamine 
(Gibco, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS, 
Invitrogen), 1% v/v penicillin/streptomycin (Gibco), and 0.1 mM nonessential amino 
acids (Invitrogen) following the manufacturer’s protocol with a media change every 
2-3 days, and passaged every 6-7 days. hMSCs (passage 4) for use in the large femur 
mold study were purchased from RoosterBio (Frederick, MD) and cultured in the 
accompanying high performance media kit from RoosterBio. To acquire the 
necessary cell numbers, we cultured the cells in several 2- and 10-stack cell culture 
flasks from Corning CellSTACK (Sigma). Cells were passaged on day 3 and cultured 
for an additional 5 days. All cells were cultured at 37°C and 5% of CO2. The 
osteogenic media was formulated as previously described [210] by supplementing 
growth media with 100nM dexamethasone (Sigma, St. Louis, MO), 10mM β-
glycerophosphate, and 173 μM ascorbic acid (Sigma). Prior to using hMSCs from the 
two cell sources, their CD biomarker analysis were compared to ensure positive for 
known hMSC marker expressions such as CD 105, CD 166, CD 90, and CD70, as 
well as negative expression of CD 14, CD 34, and CD45. Lastly, osteogenic 
differentiation of both types of hMSCs was compared over a 21-day differentiation 
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period to verify that there was no statistical difference in osteogenic gene and protein 
expressions (data not shown). 
6.2.2 Cell Encapsulation 
 hMSCs were mixed into 2% w/v alginate (Sigma) solution and used to make 3 
mm diameter alginate beads by adding the mixture dropwise (flow rate of 1 
mL/minute) into a suspension of 0.1M calcium chloride (Sigma) and stirring for 10 
minutes (100,000 cells/bead). The 1 inch construct utilized 20 million cells in 200 
alginate beads, while the femur shaped construct required 720 million cells in 7200 
alginate beads.  
6.2.3 Design and 3D Printing of Femur Mold 
 A human femur render was obtained from the open source online database 
GrabCAD (Boston, MA). The file was imported into SolidWorks (Waltham, MA) and 
the superior half of the femur was isolated. An outward extrusion of the composite 
resulted in a hollow construct with a wall thickness of 2 mm. Cylindrical pores were 
then placed at an approximate density of 1 hole per 2.83 mm
2
 surface area throughout 
the surface of the mold. Finally, the femur shell mold was split into six pieces for 3D 
printing. Cuts were made on the transverse and sagittal planes of the femur mold. The 
construct was printed out of MED610 material using an Objet500 Connexin 3D 
printer (Stratasys, Eden Prairie, MN) courtesy of the Sheikh Zayed Institute for 
Pediatric Surgical Innovation at Children’s National Health System, Washington, 
D.C. Post printing, the femur shell was sutured together using medical grade sutures 
(Ethicon, San Lorenzo, PR), and sterilized in 70% ethanol and under UV light. 
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6.2.4 TPS Bioreactor Assembly 
 For the culture of the 1 inch bone construct, the bioreactor was set-up as 
described previously[247]. Briefly, a 1-inch platinum-cured silicone growth chamber 
was loaded with 200 hMSC-seeded and 200 acellular alginate beads and connected to 
the tubing circuit and media reservoir. The flow was driven by an L/S Multichannel 
Pump System (Cole Parmer, Vernon Hills, IL) at a flow rate of 20 mL/min and media 
was changed every two days. The cells were cultured for 18 days in the 1 inch 
construct before cell analysis.  
Similarly, to fabricate the human femur bone graft, the 3D printed femur shell 
mold was filled with 7200 hMSC-loaded alginate beads and placed inside a 10-inch 
(25.4 cm) long, 4-inch (10.16 cm) diameter culture chamber (MSC Industrial Supply, 
Melville, NY).  The cell-seeded alginate bead filled mold was cultured with the femur 
head downward and the femur shaft upward in the culture chamber, as seen in Figure 
6.2d, right. Acellular alginate beads were placed in the surrounding void space of the 
culture chamber to ensure uniform media flow throughout the chamber by providing 
roughly the same resistance to flow as the hMSC-loaded alginate beads inside the 
femur shell mold. Custom-made reducing connectors were 3D printed and attached to 
either end of the chamber, and the remainder of the bioreactor was set up as described 
above. Media flow was driven at a rate of 240 mL/min to maintain velocities and 
shear stresses previously shown to enhance osteogenic differentiation of hMSCs in 
the TPS bioreactor [292]. 
 At the end of the 8 day differentiation period, the femur mold was removed 
from the growth chamber, injected with liquid alginate, and submerged in a solution 
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of 0.1M CaCl2 in hMSC growth media to aggregate the alginate beads into a single 
construct. hMSCs were isolated from specific sections of the construct (Figure 2d) 
and used for subsequent analyses. Three samples from each group were taken (n=3). 
6.2.5 Viability Assay  
 Cell viability was assessed along the length of the femur construct using a 
fluorescent Live/Dead assay (Invitrogen) following standard protocols. Beads from 
each designated section were placed in 48-well plates and incubated in 2 mM 
ethidium homodimer and 4 mM calcein AM (Molecular Probes) for 30 min. 
Fluorescent images were then taken of the entire bead using a fluorescence 
microscope (Axiovert 40 CFL, Zeiss, Thornwood, NY) equipped with a digital 
camera (Diagnostic Instruments 11.2 Color Mosaic, Sterling Heights, MI).  
6.2.6 Immunohistochemistry 
 Antigens were retrieved by exposure to steam composed of Tris base and 
EDTA buffer (pH = 8) containing TWEEN 20 for 15 minutes. Samples were blocked 
and then stained with the primary antibodies to detect BMP-2 and ALP (Abcam, 
Cambridge, MA), respectively. Protein presence was visualized with a 3,3’-
diaminobenzidine tetrahydrochloride (DAB) chromogen. Samples were 
counterstained with hematoxylin, dehydrated and cleared. Negative control slides 
were stained using the same protocol, omitting the primary antibody. 
6.2.7 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
 hMSCs from each section (head, trochanter, middle, shaft, and inner and outer 
shells) were isolated from alginate beads by dissolution in ethylenediaminetetraacetic 
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acid (EDTA) for 30 min at 37°C and a cell pellet was formed by centrifugation. The 
RNeasy Plus Mini Kit (Qiagen, Frederick, MD) was used to isolate total RNA from 
hMSCs encapsulated in alginate beads using following standard protocols. Total 
RNA was quantified using a Nanodrop Spectrometer (Thermo Scientific, 
Wilmington, DE). Isolated RNA was then reverse transcribed to cDNA using a High 
Capacity cDNA Archive Kit (Life Technologies, Frederick, MD). Quantitative RT-
PCR was performed by combining the cDNA solution with a Universal Master Mix 
(Life Technologies), as well as oligonucleotide primers and Taqman probes for ALP 
and BMP-2, and compared to the endogenous gene control glyceraldehyde 3 
phosphate dehydrogenase (GAPDH) (Life Technologies). The reaction was 
performed using a 7900HT real-time PCR System (Applied Biosystems) at thermal 
conditions of 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s at 95°C, and 1 min at 
60°C. The relative gene expression level of each target gene was then normalized to 
the mean of the GAPDH in each group. Fold change was calculated using the ΔΔCT 
relative comparative method as described previously [293] and represented in 
comparison to day 0 static control results. Samples were completed in technical 
triplicates and standard deviations are reported (n=3). 
6.2.8 Statistical Analysis 
 Each analysis was performed in triplicate (n=3). Statistical significance was 
determined by one-way analysis of variance and Tukey’s multiple-comparison test. A 
confidence interval of 95% (α = 0.05) was used for all analyses.  Mean values of 
triplicates and standard deviation error bars are reported on each figure as well as 
relevant statistical relationships. 
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6.3 Results  
6.3.1 Effect of Location on Osteogenic Differentiation in Dynamically 
Cultured 1 Inch Bone Graft 
 The TPS bioreactor has previously been used to culture hMSC-loaded alginate 
beads for the fabrication of bone constructs with a volume of approximately 2.5 cm
3
. 
However, to demonstrate the ease of use of the off-the-shelf components of the 
system, as well as assess location-based osteogenic differentiation of hMSCs, we 
expanded the growth chamber dimensions to result in a 12.8 cm
3 
construct. After 7 
days of dynamic culture in the TPS bioreactor, the alginate beads were aggregated 
into a single construct using 2% alginate and then crosslinked in additional CaCl2 
(Figure 6.1a). On days 1, 4, and 7, beads from the periphery and interior of the 
construct were analyzed for viability (Figure 6.1c) and expression of early osteogenic 
marker alkaline phosphatase (ALP) (Figure 6.1d) and late marker osteopontin (OPN) 
(Figure 6.1e) gene expression. Fluorescent staining indicated homogenous 
distribution of cells throughout the individual beads as well as continuous viability of 
cells in both experimental groups throughout the study. The expression of ALP 
mRNA increased as expected on day 7 compared to day 1 expression, yet there was 
no statistical difference between cells cultured in the peripheral and interior beads 
(Figure 6.1d). Similarly, OPN mRNA expression remained consistent between groups 
over 7 days of osteogenic differentiation (Figure 6.1e). These results indicated no 
significant difference in osteogenic differentiation of hMSCs cultured in the TPS 





Figure 6.1 Fabrication of 1-inch Bone Graft. a) Encapsulation of hMSCs in 2% 
alginate solution results in the formation of spherical alginate beads. They were 
dynamically cultured in the TPS bioreactor setup with adjustable growth chamber, 
media reservoir, and peristaltic pump. After 7 days of culture, the alginate beads were 
aggregated into a single construct (1” diameter, 1” height). b) Schematic showing 
cross-sectional view of alginate beads in 1” construct categorized into either interior 
beads or peripheral beads for analysis of cell viability and function. c) Fluorescence 
staining of interior and peripheral alginate beads on days 1, 4, and 7 depicting live 
(green) and dead (red) cells. Results indicated that cells remained viability throughout 
the graft with no visible differences between interior and peripheral culture locations. 
Scale bar represents 1000 μm. d) Gene expression of ALP and OPN mRNA on days 
1, 4, and 7. While there was an increasing trend of ALP mRNA expression by day 7, 
there was no statistical difference between the expression of interior and peripherally 
cultured cells. Similarly, no difference was observed in OPN mRNA expression on all 




6.3.2 Culture of Human Femur using Osteogenic Differentiated hMSCs 
 Creating a bone graft of sufficient size has been a major obstacle in the field 
of bone tissue engineering. Utilizing 3D printing technology, we created a hollow 
mold of the superior half of a human femur (Figure 6.2a). The printed femur was 
22.86 cm in length, 10.16 cm in width at its widest point (femur head to trochanter), 
and had an internal volume of 200 cm
3
. We created 1 mm holes throughout the 3D 
femur shell, resulting in a 62.5% porosity (with an average density of one hole per 
2.81 cm
2
) to allow for sufficient media and oxygen flow throughout the interior. The 
pieces of the femur mold were sutured together and filled with 7200 hMSC-loaded 
alginate beads (Figure 6.2b). After 8 days of dynamic culture, the femur mold was 
removed from the growth chamber and the cultured beads were aggregated into a 
single construct using 2% alginate crosslinked in 100 mM CaCl2 supplemented 
hMSC growth media (Figure 6.2c). Post aggregation, the bone construct was 20 cm in 
length, and 8.9 cm in width (femur head to trochanter). We first divided the 
composite into 4 sections (femur head, trochanter, middle, and femur shaft), followed 
by an additional inner core and outer shell for each section to analyze the cells’ 







Figure 6.2 Design, Fabrication, and Culture of Human Femur Graft. a) 
Solidworks CAD rendering of superior half of adult human femur. The mold was 
22.86 cm in length, 10.16 cm in width at its widest point (femur head to trochanter), 
and had an internal volume of 200 cm
3
. It was covered 1 mm holes throughout the 
hollowed mold with an average density of one hole per 2.81 cm
2
. b) Image of 3D 
printed femur mold after it was filled with alginate-encapsulated hMSC beads (light 
pink color). c) Image of aggregated alginate construct after 8 days of dynamic culture 
in TPS bioreactor. Its parts were categorized as femur head, trochanter, middle or 
shaft. d) Image of TPS bioreactor setup in incubator with growth chamber (circled in 
blue) containing femur mold. Schematic on right depicts TPS assembly with femur 
mold inside growth chamber and showing the direction of flow from the femur head-




 Fluorescent staining of live (green) and dead (red) cells indicated that the 
majority of cells remained viable after 8 days of dynamic culture in the TPS 
bioreactor (Figure 6.3a). There were no qualitative differences visible between cells 
from the inner core or outer shell of the construct, indicating that sufficient amounts 
of nutrients and media were supplied throughout the width of the engineered femur. 
Immunohistochemical staining for ALP and bone morphogenic protein-2 (BMP-2) 
protein (in brown, cells in blue) on day 8 showed no visible differences between early 
and late protein markers expressions (Figure 6.3b-c). However, when examining 
mRNA expression of the same markers on day 8, cells cultured in the inner (dashed 
line, 25.2-fold) and outer (solid line 39.7-fold) shells of the shaft section in the femur 
mold expressed a significantly greater amount of ALP and BMP-2 compared to other 
day 8 sections as well as day 0 static control cells (Figure 6.3d-e). Average values of 
each femur section (depicted as solid bars) demonstrated that there was no significant 
difference between ALP mRNA expression of inner and outer shells of the femur 
head, trochanter, and middle sections of the femur. Similarly, expression of BMP-2 
mRNA showed a statistically significant increase in cells cultured in the inner (dotted 
line) and outer (solid line) shell of the femur shaft as compared to the other sections 
on day 8 and the day 0 static control. Additionally, the average BMP-2 expression on 
day 8 in the femur head, trochanter, and middle sections were significantly greater 
than in the day 0 static control cells. Yet, with the exception of the femur shaft, there 
were no differences in BMP-2 expression seen between cells cultured in the inner or 








Figure 6.3 Osteogenic Differentiation of hMSCs in Adult Human Femur Mold. 
a) Fluorescence staining of hMSCs after 8 days of dynamic culture in the TPS 
bioreactor. Live (green) and dead (red) cells are shown in inner and outer shells of the 
femur head, trochanter, middle, and shaft sections of the construct. It is visible that 
the majority of cells remain viable and that no qualitative differences are observed 
between the cultured sections, indicating sufficient oxygen and nutrient supply 
throughout the construct. Scale bar represents 200 μm. b-c) Immunohistochemical 
staining of ALP and BMP-2 protein expression, respectively, of all experimental 
groups. Cells are stained in dark blue and protein in brown. No visible differences are 
seen between experimental groups in either inner or outer culture location, indicating 
homogenous differentiation of hMSCs over 8 days of dynamic culture. d-e) Average 
ALP and BMP-2 mRNA expression on day 8 compared to static day 0 control (blue 
bars). Gene expressions of cells cultured in the inner and outer shell are depicted by a 
dashed and solid line, respectively. Average ALP expression demonstrated no 
statistical difference between cells cultured in the femur head, trochanter, or middle 
sections of the femur compared to static day 0. However, an average of 32.4-fold 
increase of ALP mRNA was observed in the femur shaft. Gene expression of BMP-2 
showed statistically significant increase on day 8 in all experimental groups compared 
to the static day 0 control. Additionally, BMP-2 gene expression was approximately 
900 times greater in the femur shaft on day 8, which was significantly greater than 
expression in all other groups. Markers * and ** indicate statistical significance 





 Many bioreactor systems are limited in the size of the tissue that can be 
fabricated due to lack of oxygen that reaches the center of the graft, leading to cell 
necrosis. To solve this issue, our system utilizes smaller alginate beads (3 mm in 
diameter) that can be aggregated into a single construct of any size after dynamic 
culture in the TPS bioreactor (Figure 6.1a). The TPS bioreactor allows for enhanced 
osteogenic differentiation of hMSCs by applying fluid shear stress on the surface of 
the beads[240,247]. The culture and fabrication of the 1 inch bone graft, which is 
similar in diameter size to the shaft of a human femur, was the next step towards 
creating critically sized and clinically relevant tissue constructs for the regeneration 
of bone. Most importantly, this pilot study confirmed continuous viability of cultured 
cells throughout the culture chamber over 7 days, demonstrating that oxygen and 
nutrient supply was not different in the periphery or interior of the culture chamber 
(Figure 6.1b-c). This overcomes a major hurdle in tissue engineering, wherein cells 
cultured at the center, or core, of the graft experiences necrosis due to the 
consumption of oxygen by cells at the periphery of the graft. Additionally, osteogenic 
differentiation of hMSCs, as indicated by increased expression of ALP and OPN 
mRNA expression, proved to be similar in cells cultured throughout the chamber 
(Figure 6.1d-e). Therefore, an expansion of the TPS bioreactor growth chamber does 
not affect viability or osteogenic differentiation of hMSCs. In addition, we were able 
to demonstrate the ability to create large aggregates of alginate beads after their 
dynamic culture. The technique of utilizing additional alginate to fabricate a single 
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construct resulted in a solid hydrogel composite that was easily handled and could be 
transferred into a defect site.  
 While the TPS bioreactor enables great flexibility in the size and length of the 
tubing circuit, the cylindrical shape of the tube defines the resulting architecture of 
the construct cultured in the growth chamber. In recent years, 3D printing technology 
has emerged as a leading technological innovation, especially in medical applications. 
It has allowed for the creation of complex structures with precise architecture and 
consistency. In this work, 3D printing techniques helped fabricate an accurate model 
of an adult femur, the largest bone in the human body (Figure 6.2a). This 
demonstrates not only the potential of the technology, but also its capability to 
remove size limitations in the tissue engineering field. Additionally, the ability to 
print patient-specific molds based on magnetic resonance imaging (MRI) or 
computed tomography (CT) scans leads to more successful patient-specific care and 
tissue regenerative treatments.  
 By printing a porous 3D human femur, we were able to ensure fluid flow into 
and throughout the construct. During the dynamic culture in the TPS bioreactor, the 
femur mold was cultured with the head and trochanter at the inlet of the growth 
chamber (Figure 6.2d, right). This portion of the femur held the majority of the cell-
loaded beads and therefore needed to receive the most oxygenated media as it 
circulated via gas permeable tubing from the media reservoir to the inlet at the bottom 
towards the outlet at the top of the growth chamber. Additionally, to ensure uniform 
flow throughout the chamber, acellular alginate beads filled the void space surround 
the femur mold, as depicted by the pink patterned background in schematic 2d. After 
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aggregation of alginate beads into a single construct, it was divided into further 
segments for viability and gene expression analysis.  
 On day 8, cell viability remained high in both the inner and outer shell of each 
section (Figure 6.3a), with no visible differences observed. This is an important and 
momentous achievement for any large tissue-engineering construct. The advantage of 
dynamically culturing small alginate beads in the TPS bioreactor prior to aggregation 
and implantation is most evident with the high cell viability result. Additionally, the 
immunohistochemical staining of early osteogenic marker ALP and osteogenic 
growth factor BMP-2 indicated only subtle differences in protein expression between 
the experimental groups on day 8, with slightly greater staining on femur shaft 
samples. Therefore, the cells are experiencing similar culture environments that 
produce homogenous expression of protein throughout the construct.  
 The average mRNA expression of ALP (Figure 6.3d, blue bars) showed no 
significant differences between the femur head, trochanter, or middle sections 
compared to day 0 static control cells. However, a significant increase in expression 
was observed in cells cultured in the inner and outer femur shaft (26.2- and 39.7-fold 
change, respectively), compared to the static day 0 control. A similar pattern was seen 
in the BMP-2 mRNA expression, in which the inner and outer shell of the femur shaft 
expression was statistically greater than in the other groups on day 8. In addition, the 
femur head, trochanter, and middle sections expression significantly greater BMP-2 
mRNA compared to day 0 static control (3.8-fold, 3.2-fold, and 4.8-fold, 
respectively). We hypothesize that this substantial increase in ALP and BMP-2 may 
be attributed to growth factor production and update from cells from the inlet and the 
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outlet of the growth chamber. In particular, we believe that there is a growth factor 
gradient created during uni-directional flow in the growth chamber, which is 
generated when growth factors are released from cells cultured at the inlet and taken 
upstream by the fluid flow to cells cultured at the outlet, where they enhance 
functions like osteogenic differentiation. We have been able to show diminishing 
effects of this phenomenon when periodically alternating the direction of the flow 
inside the growth chamber. Therefore, we believe the direction of the flow can 
influence the expression of osteogenic markers in differentiating hMSCs. While the 
expression of osteogenic mRNA was much higher in cells cultured in the femur shaft, 
we observed trends of increased BMP-2 expression over 8 days of dynamic culture in 
all sections of the graft. It is also interesting to note that the outer shell of the femur 
construct expressed greater amounts of osteogenic mRNA in almost all groups on day 
8. This could be seen as an advantageous benefit of the culturing system, in which the 
outer shell experiences relatively accelerated development to form the compact and 
stiffer cortical bone tissue, leading to structural support for the growth of the interior 
trabecular bone, which is spongy and weaker in mechanical strength. 
6.5 Conclusion 
 Although this study has demonstrated major strides towards developing a 
bone graft fit for clinical application, there are still limitations that need to be 
addressed. This one-time proof of concept provides invaluable information about the 
ability to create a high volume engineered bone construct, yet additional studies with 
longer culture periods will generate more data and knowledge on the capabilities of 
the system. Although bone-marrow derived mesenchymal stem cells have been used 
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in broad tissue engineering applications, a limitation in their osteogenic 
differentiation has been found when used in a bone defect composed of cells of 
neural-crest origin compared to cells of mesoderm origin [294]. Therefore, the stem 
cell origins as well as final defect destination need to be considered when designing a 
bone tissue engineering graft. Additionally, the current setup utilizes alginate 
hydrogels as a cell deliver and culturing environment, due to the natural polymer’s 
known non-cytotoxic and bio-inert properties. However, its lack of mechanical 
strength makes it non-ideal for future bone tissue engineering applications without 
further additions or modifications. Therefore, we plan to utilize a scaffold sleeve 
carrier made from a polymers such as poly(propylene fumarate), which has 
mechanical properties close to bone [295], that can be utilized to 3D print the femur 
shell and then be directly implanted into the defect site after aggregation of the 
alginate beads. Additionally, a drawback of the current scaffold material includes the 
lack of cell-cell contact between differentiating hMSCs in separate alginate beads 
during initial dynamic culture. With the aggregation of scaffolds using additional 
alginate, we hope that cells will be able to migrate within the constructs after in vivo 
implantation. More importantly, in order to bring this technology from bench to 
bedside, a vascular network will be vital; without it, the encapsulated cells at the core 
of the construct will not survive after implantation into the patient. Like many organs, 
bone contains an intricate vasculature that maintains viability throughout the tissue.  
Therefore, we are developing techniques to incorporate vascular networks within the 
engineered bone tissue for improved incorporation into the defect and surrounding 
tissue.  With these next steps, we anticipate the fabrication of a fully functional, size 
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and patient specific tissue engineered bone construct that can be dynamically cultured 
in the TPS bioreactor and then directly implanted into a bone defect.   
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Chapter 7:  Dynamic Coculture of Mesenchymal Stem Cells and 
Endothelial Cells for Bone Tissue Engineering 
7.1 Introduction  
 A major challenge of developing a large bone tissue engineering construct is 
delivery of nutrients and oxygen to the core once it has been implanted in the 
patient’s defect site. In vivo, cells are supplied with vital molecules via nearby blood 
vessels that carry nutrients and waste to and from the cells. However, without a pre-
established vascular network developed in vitro prior to implantation, the diffusion of 
important nutrients is limited to 100-200 μm from the host vasculature, unable to 
maintain viability of the majority of the construct [2,296]. Therefore, in order to 
establish a viable system for in vivo implantation, the complex interaction between 
the two main cell types for bone tissue engineering applications, human mesenchymal 
stem cells (hMSCs) and endothelial cells, need to be better understood. This 
knowledge will allow for the creation of a prevascularized engineered construct prior 
to insertion into a patient.  
The use of in vitro cocultures has been one of the most explored options for 
this application [20,297–299]. A range of coculture methods investigate the 
interactions between the endothelial cells and osteogenic differentiated mesenchymal 
stem cells or osteoblast like cells as they are inherently linked during the osteogenic 
and angiogenic process [300–302]. The formation of micro-vasculature in some 
coculture conditions has been demonstrated [43,44,138,225], however, few have been 
applied for in high-volume tissue engineering constructs, which require an extensive 
prevascularized network to remain viable in vivo [303].   
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Here we investigate the important role of coculture parameters that influence 
the osteogenic and angiogenic potential of hMSCs and endothelial cells, respectively. 
First, we examine the role of scaffolds on cocultures, specifically, the native content 
of cell-binding sites that exist in natural polymers like collagen but are less abundant 
in alginate. The sodium alginate polymeric backbone presents no intrinsic cell-
binding domains, but can be used to regulate gel mechanical properties. On the other 
hand, natural collagen fibrils present specific peptide sequences that can be 
recognized by cell surface receptors, therefore allowing for cell adhesion and 
spreading that better recreates many in vivo contexts [304,305]. The second parameter 
tested was the influence of shear stress on the coculture system. Dynamic culture 
conditions can be created in a perfusion bioreactor that mimics in vivo conditions. We 
have previously demonstrated the benefits of the tubular perfusion system (TPS) 
bioreactor on osteogenic differentiation of hMSCs due to the applied shear flow and 
the increased oxygen and nutrient supply to the cultured cells [205,240,247,285,306].  
To this end, the objective of this study is to determine the importance of 
specific environmental parameters in HUVEC and hMSCs coculture: 1) cell coculture 
proximity, and 2) effects of shear stress on hMSC osteogenesis and HUVEC 
angiogenesis. 
7.2 Materials and Methods 
7.2.1 Cell culture 
Bone marrow derived hMSCs were purchased from RoosterBio, Inc. and 
cultured in the accompanying high performance media kit from RoosterBio. hMSCs 
were passaged and given fresh media on Day 5. They were harvested at passage 3 for 
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encapsulation. HUVECs were purchased from Lonza and cultured in endothelial cell 
growth media (Lonza). HUVECs were given fresh media every 2-3 days and 
passaged on Day 5. HUVECs were harvested at passage 3 for encapsulation.  All cells 
were cultured at 37°C with 5% CO2. 
7.2.2 Alginate bead scaffold fabrication and hMSC encapsulation 
 Alginate beads were fabricated using 2% alginate solution (Sigma), 
homogenously mixed with hMSCs (100,000 hMSCs/bead), and crosslinked in 
100mM CaCl2 by dropwise addition of the solution through an 18G needle and 
syringe. The beads were stirred for 10 minutes to allow for complete crosslinking of 
the alginate and placed in hMSC growth media until use.  
7.2.3 Thin hydrogel fabrication for cell adhesion 
 2% alginate and 4mg/mL collagen hydrogels were fabricated to test hMSC 
and HUVEC adhesion to the scaffolds. Cylindrical alginate gels were created using 
molds (20mm in diameter, 2mm in height) and diffused with 100mM CaCl2 for 
crosslinking and then transferred to 12 well plates. Collagen hydrogels were made 
directly in the wells and crosslinked at 37°C for 30 minutes. Hydrogels were stored in 
PBS until cell seeding. 
7.2.4 Cell adhesion assay 
 hMSCs and HUVECs were lifted using trypsin/0.25% EDTA (Life 
Technologies) and counted. They were seeded onto the hydrogels in a concentrated 
solution of 100,000 cells/100uL for 1 hour at 37°C. Additional media was added after 
1 hour and cells were allowed to adhere for 3 more hours. Cells were seeded on TCPS 
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as a positive control for cell attachment. After 4 total hours of incubation, hydrogels 
were gently washed 3 times with PBS. To visualize and quantify cell adhesion, a live-
dead assay (Invitrogen) was performed following standard protocol. Gels were 
imaged using a fluorescent microscope (Axiovert 40 CFL with filter set 23; Zeiss) 
equipped with a digital camera (Diagnostic Instruments 11.2 Color Mosaic). 
Adhesion was also quantified using a plate reader and  
7.2.5 Collagen hydrogel formation/encapsulation 
All cells were encapsulated in 4mg/mL rat tail derived type I collagen 
(Corning) and prepared following manufacturer’s instructions. The desired collagen 
concentration was kept on ice while cells were harvested and centrifuged at 500g for 
5 minutes. Collagen was added to the cell pellets and mixed and kept on ice. Small 
gels were created by pipetting 3.33μL of the collagen/cell mixture onto UV-sterilized 
parafilm and crosslinking for 7 minutes at 37°C. The beads were washed off the 
parafilm and collected. We created 6 experimental groups: hMSCs in collagen in 
static conditions, hMSCs in collagen in dynamic condition, HUVECs in collagen in 
static conditions, HUVECs in collagen in dynamic conditions, a coculture of hMSCs 
and HUVECs in collagen in static conditions, and a coculture of hMSCs and 
HUVECs in collagen in dynamic conditions.  
7.2.6 Static & dynamic culture 
Scaffolds in the static groups were cultured in 6 well plates. Dynamic groups 
were placed in a TPS bioreactor as previously described. Each group was loaded into 
a ¼” by 5” growth chamber and connected to the tubing circuit and media reservoir.  
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The flow was driven by an L/S Multichannel Pump System (Cole Parmer) at a flow 
rate of 3 mL/min and media was changed every 3 days. All groups were cultured at 
37°C with 5% CO2. All coculture groups were cultured in mixture of 1:1 ratio of 
osteogenic media to endothelial cell growth media. Osteogenic media was prepared 
by supplementing growth media containing High Glucose Dulbecco’s modified 
Eagle’s medium with l-Glutamine (Gibco), supplemented with 10% fetal bovine 
serum (Invitrogen), 1% v/v penicillin/streptomycin (Gibco), and 0.1 mM nonessential 
amino acids (Invitrogen) with 100 nM dexamethasone (Sigma), 10 mM b-
glycerophosphate, and 173 mM ascorbic acid (Sigma).  
7.2.7 RNA extraction 
Cell samples from each group were isolated from collagen gels by dissolution 
in 1mg/mL collagenase (Sigma) for 60 min at 37°C and a cell pellet was formed by 
centrifugation and washed with PBS three times. The RNeasy Plus Mini Kit (Qiagen) 
was used to isolate total RNA following standard protocols. Total RNA was 
quantified using a Nanodrop Spectrometer (Thermo Scientific).  
7.2.8 Real-time quantitative polymerase chain reaction (RT-qPCR) 
  Isolated RNA was then reverse transcribed to cDNA using a High Capacity 
cDNA Archive Kit (Life Technologies). RT-qPCR was performed by combining the 
cDNA solution with a Universal Master Mix (Life Technologies), along with 
oligonucleotide primers and Taqman probes for ALP, BMP-2, and OCN (hMSCs and 
coculture samples) and VEGF and PECAM (HUVEC and coculture samples), and 
compared to the endogenous gene control glyceraldehyde 3 phosphate dehydrogenase 
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(GAPDH; Life Technologies). The reaction was performed using a 7900HT real-time 
PCR System (Applied Biosystems) at thermal conditions of 2 min at 50°C, 10 min at 
95°C, 40 cycles of 15 s at 95°C, and 1 min at 60°C. The relative gene expression 
level of each target gene was then normalized to the mean of the GAPDH in each 
group. Samples were completed in technical triplicates and standard deviations are 
reported (n = 3). 
7.2.9 Immunohistochemistry 
 At each timepoint, collagen gels were fixed in 4% paraformaldehyde for 2 
hours at RT, dehydrated and embedded, and sectioned into 10μm slices.  Antigens 
were retrieved by exposure to steam composed of Tris base and EDTA buffer (pH = 
8) containing TWEEN 20 for 15 minutes. Samples were blocked and then stained 
with the primary antibodies to detect BMP-2 and ALP (Abcam, Cambridge, MA) in 
hMSCs, PECAM and VEGF in HUVECs, and BMP-2 and PECAM in the coculture. 
FITC and Cy-5 tagged secondary antibodies were used to visualize the protein, while 
DAPI stained the nucleus. Samples were imaged using a LSM700 confocal 
microscope (Zeiss).  
7.2.10 Cell Viability Assay 
  Cell viability was assessed using a fluorescent Live/Dead assay (Invitrogen) 
following standard protocols. Gels were placed in 1.5mL microcentrifuge tubes 
(Fisher Scientific) and incubated in 1 mM ethidium homodimer and 2 mM calcein 
AM (Molecular Probes) for 30 min. Fluorescent images were then taken of the entire 
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bead using a fluorescence microscope (Axiovert 40 CFL; Zeiss) equipped with a 
digital camera (11.2 Color Mosaic; Diagnostic Instruments). 
7.3 Results 
7.3.1 Coculture of hMSCs in alginate and HUVECs in collagen scaffolds 
 We first examined coculture parameters between hMSCs and HUVECs by 
culturing them in alginate and collagen, respectively, under either static or dynamic 
conditions (Figure 7.1a). BMP-2 immunostaining of hMSCs showed increased 
presence of protein (brown) after 14 days of coculture, especially in the dynamically 
cultured group (Figure 7.1b). The morphological change seen by day 14 in dynamic 
conditions indicated cell spreading of the hMSCs. Gene expression of mRNA also 
showed enhanced expression in both cells cultured in the TPS bioreactor. BMP-2 
gene expression in dynamically cultured hMSCs increased 3-fold after 7 days and fell 
to 2-fold after 14 days, compared to day 0 values (Figure 7.1c, gray). In contrast, 
static BMP-2 values remained fairly constant over the 14 day period (Figure 7.1b, 
black). The impact of dynamic culture was also visible in HUVEC gene expression of 
VEGF, which linearly increased over 14 days to 3.5-fold change compared to day 0 
values (Figure 7.1d, gray). Statically cultured cells reached only a 1.8-fold increase 






Figure 7.1 Coculture in Alginate and Collagen Scaffolds. A) Experimental setup 
depicts a 7 day static preculture of hMSCs encapsulated in alginate scaffolds, 
followed by a 14 day dynamic or static coculture with HUVECs encapsulated in 
collagen scaffolds. B) BMP-2 immunostaining demonstrates increase in BMP-2 
production (brown) in hMSCs (dark blue nucleus). C) BMP-2 mRNA expressions in 
hMSCs significantly increases over 14 days in dynamic culture but stays constant 
static culture. D)  VEGF mRNA expressions in HUVECs significantly increases over 
14 days in dynamic culture and shows an increase on day 7 in static before decreasing 
back close to basal levels. The symbol ‘*’ indicates statistical significance within 




7.3.2 Cell adhesion on collagen and alginate  
We examined the importance of binding sites in natural polymers like alginate 
and collagen on hMSC and HUVEC adhesion and spreading (Figure 7.2a). When 
seeded on top of alginate hydrogels, hMSCs remained rounded in morphology and 
very few attached after the 4 hour incubation (Figure 7.2c, top row). HUVECs 
showed slightly higher attachment ability in comparison, however, little spreading 
was observed during this period (Figure 7.2c, bottom row). On the other hand, greater 
number of cells remained attached on collagen hydrogels, for both hMSCs and 
HUVECs, with a distinctly greater number of elongated HUVECs. Cells seeded on 
TCPS as positive control adhered on the well surface, with clear spreading and 
elongated morphology visible. It is important to note that HUVECs, while fully 
spreading out, most adhered around the edge of the well, due to the small and 
concentrated media volume at seeding. These cell adhesion results were conferred 
using a microplate reader to determine total fluorescence (in RFU) (Figure 7.2d). 
Based on the detected fluorescence, significantly greater number of hMSCs and 
HUVECs adhered to collagen compared to alginate hydrogel surfaces. In the case of 
HUVEC, greater fluorescence was detected on collagen compared to TCPS, which 






Figure 7.2 Cell Adhesion and Osteogenic Differentiation in Collagen Scaffolds. 
A) Experimental setup for cell adhesion study on alginate and collagen substrates, 
and TCPS as positive control. B) Experimental setup to investigate the effect of 
collagen encapsulation on osteogenic differentiation compared to TCPS as a control. 
C) Fluorescence images of hMSCs or HUVECs seeded on alginate, collagen, or 
TCPS substrates, taken at 2.5x magnification. D) Quantification of fluorescence 
signal read via a spectrophotometer at excitation of 494nm and emission of 517nm 
for both hMSCs and HUVECs. Units are listed as RFU (relative fluorescence units). 
E) Fluorescence images of hMSCs labeled with live (green) and dead (red) stain on 
TCPS or encapsulated in 3D collagen scaffolds. F) Gene expression of osteocalcin 
(OCN) mRNA in hMSCs over 14 days. Production was statistically greater in 
collagen scaffolds compared to the TCPS control. G) Gene expression of BMP-2 
mRNA in hMSCs shows significantly increased expression in 3D collagen compared 
to TCPS. The symbol ‘*’ indicates statistical significance within groups at a 




7.3.3 Osteogenic differentiation of hMSCs in collagen scaffolds 
 The ability of hMSCs to successfully differentiate in osteoblasts while 
encapsulated in collagen scaffolds was observed through morphological changes and 
determined through gene expression of late differentiation marker osteocalcin (OCN) 
and general osteoblast marker bone morphogenic protein-2 (BMP-2). Results were 
compared to hMSCs seeded in 2D on TCPS. As visible in the fluorescence live-dead 
staining, hMSCs greatly elongated when encapsulated in collagen compared to 2D 
TCPS, resulting in greater cell length but smaller cell width (Figure 7.2e). 
Additionally, hMSCs expressed significantly greater amounts of OCN and BMP-2 at 
every timepoint over the 14 day differentiation study (Figure 7.2f-g).  
7.3.4 Effects of dynamic culture on hMSC and HUVEC coculture in collagen 
scaffolds  
 HUVECs and hMSCs were encapsulated in collagen scaffolds and cultured 
for 14 days in static or dynamic conditions to determine effects on osteogenic and 
angiogenic potential of the cells (Figure 3a). Fluorescence microscopy of the cell-
encapsulated hydrogel indicated high viability of all three groups (hMSCs, HUVECs, 
and hMSCs+HUVECs), with great elongation of hMSCs visible while HUVECs 
remained more rounded in morphology (Figure 3b). Interestingly, cells formed 
aggregates when cocultured in collagen, more visibly in dynamic culture compared to 
static coculture (white arrows). 
 We examined gene expression of common osteogenic markers (ALP and 
BMP-2) in hMSCs and angiogenic markers (PECAM and VEGF) in HUVECs during 
mono- and cocultures (Figures 3c-e). As seen in Figure 3c), ALP mRNA expression 
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increased moderately over 7 days in hMSCs cultured alone in collagen. Expression in 
dynamic cells was statistically greater on days 1 and 7 compared to static cells (purple 
and orange striped bars vs. purple and orange solid bars). Similarly BMP-2 mRNA 
expression in hMSC monoculture significantly increased over 7 days, with 
dynamically cultured cells leading the way until day 7, when statically cultured cells 
expressed similar levels, 9.5 and 10.2 fold, respectively. Angiogenic marker 
expressions in monocultured HUVECs followed a similar trend, where when cultured 
in the TPS bioreactor produced significantly greater amounts of PECAM and VEGF 
compared to the control HUVECs in static culture (Figure 3d). 
 More interestingly, coculture of hMSCs and HUVECs in collagen scaffolds 
increased expression of all four markers, independent of their static or dynamic 
culture environment (Figure 3e). For example, ALP expression, while staying 
constant over the culture period, reached 4-fold increasing levels on day 1 in dynamic 
culture and day 3 in static culture, but were not reached until day 7 in hMSC 
monoculture. During coculture, BMP-2 expression in hMSCs was impressively 
increased, reaching an 18.2-fold increase in the dynamic group and 12.4-fold increase 
in the static group by day 7. PECAM and VEGF expressions were also greater in 
coculture conditions compared to the HUVEC monoculture expressions. Specifically, 
PECAM expression increased 5.5- and 6.0-fold over day 1 values in static and 
dynamic conditions, respectively, albeit they were not statistically different from one 
another. VEGF mRNA expressions also significantly, with day 7 dynamic expression 
twice as high as day 7 static expression. 
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 These mRNA expression results were confirmed using immunofluorescence 
staining (Figure 3f). hMSCs in monoculture were stained with BMP-2 antibody and 
showed visible staining throughout the cell by day 7 (red with blue nucleus), in both 
static and dynamic culture. HUVEC monoculture stained more positive for CD-31 
(green) on day 7 in static culture than in dynamic culture, but vice versa with VEGF 
(red) staining. hMSCs and HUVECs cocultured in collagen scaffolds were stained for 
BMP-2 (red) and CD31 (green) with DAPI labeled nuclei (blue). There were visibly 
greater amounts of BMP-2 compared to monocultured hMSCs, with the greatest 
amounts seen in cells cultured in the TPS bioreactor. An 80x zoom of the area 
(highlighted in white box), displays diffused BMP-2 (red) throughout the cellular 










Figure 7.3 Effect of Dynamic Culture on hMSCs and HUVEC coculture. A) 
Experimental setup of cell encapsulation groups: hMSCs in collagen, HUVECs in 
collagen, or hMSCs and HUVECs in collagen. Cell-seeded scaffolds were cultured in 
static well plates or in the TPS bioreactor under dynamic flow conditions.  B) E) 
Fluorescence viability images of hMSCs labeled with live (green) and dead (red) stain 
on  3D collagen scaffolds after 1, 3, or 7 days of static or dynamic culture. Scale bar 
represents 100 μm. C) Gene expression of ALP and BMP-2 in hMSCs monocultured 
in static (solid bars) or dynamic (striped bars). Overall, dynamic coculture resulted in 
the highest expression of ALP and BMP-2 expression by day 7. D) Gene expression 
of PECAM and VEGF in HUVEC monocultured in static (solid bars) or dynamic 
(striped bars). Overall, dynamic coculture resulted in the highest expression of 
PECAM and VEGF expression by day 7. E) Gene expression of ALP, BMP-2, 
PECAM, and VEGF in hMSC and HUVEC cocultured in static (solid bars) or 
dynamic (striped bars). Overall, the synergistic effect of coculture and dynamic 
coculture resulted in the highest expression of all four markers by day 7. The symbol 
‘*’ indicates statistical significance within groups at a timepoint (p<0.05). F) 
Immunofluorescence staining of hMSCs, HUVECs, and coculture in static and 
dynamic. hMSCs were stained for BMP-2 (pink/red), counterstained with DAPI 
(blue). HUVECs were stained for CD31 (green), VEGF (red), and counterstained 
with DAPI (blue). Cocultured samples were stained for BMP-2 (pink/red), CD31 
(green), and counterstained with DAPI (blue). Images were taken at 40x with an 





Alginate and collagen are natural polymers that have been shown to be 
biodegradable, non-toxic, and maintain viability of encapsulated cells. Although 
alginate has many favorable properties for tissue engineering applications, it lacks 
specific interaction with cells. Binding sites like Arg-Gly-Asp (RGD) sequences are 
preserved in collagen fibrils, allowing cells to interact and adhere to the hydrogel.  
Using these alginate scaffolds, we have shown successful differentiation of 
hMSCs into osteoblasts, in both static and dynamic culture conditions. However, in 
order to progress towards a prevascularized bone construct, we coculture the two 
main cell types involved in this process: osteogenic differentiating hMSCs and 
HUVECs. Type I collagen being the most abundant extracellular protein surrounding 
endothelial cells, we encapsulated HUVECs in collagen hydrogels. Together with 
alginate-encapsulated hMSCs, they were cultured in either static or dynamic 
conditions. The objective behind this coculture system was to provide an environment 
where cytokines and growth factors could be exchanged between HUVECs and 
hMSCs, similar to in vivo environments, where cells may be in proximity but not in 
cell-to-cell contact. After 14 days of coculture, both cell types showed little response 
towards osteogenesis or angiogenesis when cultured in static conditions. However, 
dynamic coculture resulted in enhanced BMP-2 gene production in hMSCs and 
increased VEGF gene production in HUVECs.  More notably was the morphological 
change of the hMSCs after 14 days of coculture. Cells started to extend outward, 
which may exhibit behavior of pericytes that support endothelial cells during 
angiogenesis. The role of MSCs as pericytes has been widely discussed in the field of 
 111 
 
tissue engineering, with evidence showing that MSCs can transform to take on the 
role of support cells when cultured in proximity of endothelial cells [129,307]. This 
idea would indicate a cytokine or growth factor communication between the 
cocultured cells, to which the hMSCs can interpret and migrate to in response. 
In order to further investigate this idea of HUVEC and hMSCs migration 
during coculture, we decided to encapsulate the cells in the same natural polymer 
hydrogel scaffold. Collagen, being an abundant protein also found in bone, we chose 
it as a coculture cell carrier. However, first, the effect of natural binding sequences in 
alginate and collagen hydrogels on HUVEC and hMSC seeding was examined. The 
natural higher content of RGD-like binding sites on collagen allowed hMSCs and 
HUVECs to more readily bind to the surface, as observed in the adhesion assay 
fluorescence images (Figure 1b). Both cell types not only adhered but showed early 
signs of spreading. Although the cells were more confluent and spread on TCPS, with 
additional time, we believe the cells on collagen could reach similar confluency and 
adhesion. The quantitative fluorescence measurement of cell adhesion (Figure 1b) 
also indicated statistically greater numbers of HUVECs and MSCs on collagen 
compared to alginate. Greater RFUs were detected in hMSCs seeded on collagen than 
in TCPS, contradicting the fluorescence images. However, this can be explained by 
the seeding and attachment of hMSCs on the outer ring of the TCPS well, rather than 
forming a homogenous monolayer on the entire surface. This adhesion pattern 
resulted in lower RFUs detected during the microplate spectrophotometry.  
We have demonstrated successful hMSC differentiation potential in alginate 
scaffolds, and wanted to confirm similar outcomes in collagen scaffolds. When 2D 
 112 
 
differentiation on TCPS was used as a control, hMSCs expressed significantly greater 
amounts of OCN and BMP-2 throughout the 14-day study (Figure 2g-h). We attribute 
these significant increases not only do the 3D environment, which mimics the cells’ 
natural environment, but believe the additional biological cues received from collagen 
are able to enhance the osteogenic differentiation process.  
Next, we proceeded to evaluate the effects of coculture on hMSC osteogenic 
differentiation and HUVEC angiogenic vascular network formation. Cells were either 
mono- or cocultured in static or dynamic conditions. Under static conditions, cells 
were placed into 6 well plates and provided similar amounts of media as in the TPS 
bioreactor for dynamic culture, ensuring similar cytokine and endogenous growth 
factor concentrations. Fluorescence microscopy images showed elongation and 
spreading of hMSC morphology, which was not visible in the HUVEC population 
(Figure 2b). As others have noted, depending on the encapsulated cell type, hydrogels 
like collagen will greatly contract and shrink as cells inherently pull on the scaffold 
during adhesion and spreading. This was clearly visible in the hMSC and coculture-
encapsulating collagen gels, which were half the size as the HUVEC collagen 
scaffolds by day 3. Interestingly, the aggregates of cells seen in the coculture group 
(Figure 3d, white arrows) may indicate preferences for the cells to remain in clusters 
in order to remodel their surrounding extracellular matrix.  
Gene expression results of the study showed clear benefits of coculture in 
dynamic environments for the purpose of osteogenic differentiation in hMSCs and 
HUVEC angiogenesis compared to static and/or monocultures. With the exception of 
ALP expression by day 7, which remained similar compared to hMSC monoculture 
 113 
 
ALP expression, all other genes showed multiple fold increases over their 
monoculture counterparts. For example, we observed an 18.2 versus 10.8-fold change 
of BMP-2 expression in dynamic culture on day 7 compared to day 1. Angiogenic 
markers PECAM and VEGF also showed enhanced expression in coculture groups, 
reaching 6-fold and 10-fold increases, respectively.  
7.5 Conclusion 
This series of experiments indicated that coculture parameters for hMSCs and 
HUVECs are extremely important in providing the appropriate environment to push 
the cells towards osteogenesis and angiogenesis, respectively. The culture distance 
between the two cell types has proven to be crucial in enhancing these processes. In 
particular, cell-to-cell contact in the collagen hydrogel scaffold demonstrated the 
greatest benefit to hMSCs and HUVECs, compared to when they were cocultured in 
separate scaffolds. Additionally, while we have previously showed enhancement of 
osteogenesis in hMSCs under dynamic flow, the improvements in HUVEC 
expression of angiogenic markers in both mono- and coculture environments 





Chapter 8: Summary and Future Directions 
8.1 Summary 
 The overall goal of this work was to develop a method to prevascularize tissue 
engineered bone construct for the application of high volume bone defects via the 
coculture of hMSCs and HUVECs in the TPS bioreactor. This goal was achieved 
through several steps that allowed for understanding of the cell function, 
environmental stimuli, cell-cell interactions during osteogenesis and angiogenesis, as 
well as the impact of dynamic culture on individual or combined cell culture.  
 The first objective of this work was to capitalize on the benefits of the PS 
bioreactor and further augment cell function during dynamic culture. We utilized 
growth factor loaded microparticles as a delivery system to alginate-encapsulated 
hMSCs. With the aid of collaborators, we fabricated BMP-2 and VEGF loaded PLGA 
microparticles that provided sustained release of important osteogenic growth factors 
to our cells while cultured in static and dynamic conditions. We found that there was 
a synergistic link between growth factor delivery and shear flow on osteogenic 
differentiation of hMSCs. This unique method of fabricating PLGA microparticles 
allows for high encapsulation efficiency of growth factors while proving to be non-
cytotoxic to cells and delivering sustained and bioactive cytokines.  
 The second objective was to characterize the TPS bioreactor to better 
understand the mechanism behind its ability to enhance osteogenic differentiation of 
hMSCs. While the shear stress applied by the dynamic culture has been previously 
described by our lab, this study indicated that the local effect it has on cells within the 
axial growth chamber was not uniform. When dividing the tubular growth chamber 
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into ‘inlet’ and ‘outlet’ sections, we discovered through computational modeling that 
while shear stress on the surface of hMSCs-encapsulated alginate beads was constant, 
the direction of flow resulted in enhanced osteogenic marker expression in cells 
cultured at the outlet. This phenomenon was eliminated when the direction of the 
flow was alternated every day for 7 days. Additionally, we could enhance the 
differentiation of hMSCs in both experimental groups through the delivery of BMP-2 
growth factor to the system. These results suggest that the flow of the TPS bioreactor 
is responsible for the delivery of growth factors and cytokines from cells at the inlet 
and carries them downstream to cells at the outlet, where they can be used to improve 
cell function. We believe that this aspect of control in the TPS bioreactor allows for 
the culture of interdependent, yet distinct cell populations.  
 The third objective of this work was to scale-up the TPS bioreactor for the 
fabrication of a patient-specific, high-volume tissue engineered bone construct to 
regenerative critical sized defects. Previous work from our lab has demonstrated the 
capabilities of the TPS bioreactor to improve osteogenic differentiation of cells 
encapsulated in alginate scaffolds. However, in order to provide a clinically relevant 
sized construct, the system has to be greatly expanded. In this study, we demonstrated 
successful scale-up of the TPS bioreactor system for an adult femur sized and shaped 
construct, ranging from flow rate to growth chamber to cell capacity. The results 
indicated that cells not only remained viable in this setup, proving sufficient oxygen 
and nutrient supply, but that osteogenic differentiation occurred over the 8 day culture 
period through the application of shear stress. We see this as a major step towards 
creating a patient-specific, tissue engineered bone construct of relevant size that will 
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fill a void in the regenerative medicine field where large tissue replacements are 
greatly needed. 
 The fourth objective focused on developing a coculture method for hMSCs 
and HUVECs such that they could undergo osteogenesis and angiogenesis, 
respectively. To investigate this objective, we first looked at the coculture of the two 
cell types in separate scaffolds, alginate and collagen. We showed that there was little 
effect when cultured separately, indicating a need for closer proximity of the cells, 
like cell-cell contact, in order to provide enhanced osteo- and angiogenesis. Next, we 
tested the effect of dynamic culture on a coculture of hMSCs and HUVECs in 
collagen scaffolds. Similarly, these results suggested that a coculture can enhance cell 
functions compared to monoculture, and that dynamic culture augments this process 
even more. Taken together, we demonstrate the synergistic effects of coculture in a 
dynamic environment for the application of osteogenesis and angiogenesis in hMSCs 
and HUVECs, respectively.  
 In conclusion, these studies have demonstrated the advantages of the TPS 
bioreactor for bone tissue engineering as well as prevascularization of bone 
constructs. Specifically, we have further characterized the system, utilized it for a 
scaled-up setup, as well as combined two distinct cell populations for the application 
for vascularized bone. Taken together, the knowledge of the relationship between 
endothelial cells and mesenchymal stem cells with the capabilities of the TPS 
bioreactor can be leveraged to fabricate a single, high-volume tissue construct that is 
prevascularized and patient specific.  
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8.2 Future Directions 
 In this work, we focused on the characterization and scale-up of the TPS 
bioreactor for the purpose of fabricating a prevascularized tissue engineered bone 
construct. Each of the 4 objectives contributes to our understanding of the cells’ 
interaction with other cells, with the scaffold, and with the dynamic culture system as 
a whole. With this knowledge, we have made major strides towards fabricating high-
volume tissue engineering construct. Described below are several steps that may 
bring this concept closer to a clinical reality. 
 In chapter 4, we discovered the synergistic effects of growth factors like 
BMP-2 and VEGF with dynamic culture on osteogenic differentiation of hMSCs. In 
addition to evaluating the beneficial effects of sustained growth factor release on 
MSCs, a similar effect may be seen in HUVECs. Therefore, further studies on 
specific growth factors, such as VEGF or platelet-derived growth factor (PDGF), in 
dynamic culture and their role in vascularization would greatly advance the efforts in 
establishing a prevascularized network for a variety of engineered tissues.  
Furthermore, the results of objective 1 (Chapter 5) demonstrated the unique 
growth chamber environment that is created in our uniaxial TPS bioreactor. The 
varying growth factor and cytokine distribution observed in the TPS bioreactor 
growth chamber could be further explored through direct measurement of endogenous 
cytokine expression by hMSCs. Additionally, this bimodal system could be used to 
coculture hMSCs and HUVECs to better understand their paracrine signaling 
mechanisms that we see in our current coculture experiments. Lastly, by investigating 
the intricate mechanisms of the TPS bioreactor, we are able to expand the utility of 
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our system to other tissue engineering applications like the coculture of the three 
zonal chondrocyte types for the regeneration of cartilage. 
 Our findings for objective 3 (Chapter 6) describe the scalability of the TPS 
bioreactor for clinically relevant defects that cannot be healed by the host itself and 
require a regenerative therapy alternative. This is the first time a bone tissue 
engineering construct of that magnitude and size has been fabricated. The results of 
this objective indicated sufficient oxygen supply along the entire construct through 
high viability and cell function. Therefore, with the functionality of a perfusion 
bioreactor that can culture a wide range of sizes, additional studies on the long-term 
effects of high-volume cultures would open up the field to more clinically relevant 
therapies.  Additionally, the 3D printing technology gives way to patient-specific 
constructs that can be custom made and fitted, allowing for specific and highly 
detailed grafts. 
 The last objective (Chapter 7) addresses a major hindrance in the field of 
tissue engineering. The lack of vasculature prevents not only bone grafts, but almost 
all other large tissue engineered organs from successful patient implantation. 
Therefore, it is vital to overcome this barrier to bring the field of tissue engineering 
closer to a clinical application. The coculture system described in this work suggests 
the importance of cell-to-cell contact and physical stimulation in order to enhance the 
paired environment. Further studies to investigate the exact mechanism by which the 
cells communicate and function in synchronization will allow for a more cohesive 
graft fabrication. Additionally, the efficiency of the graft’s integration into the host 
through anastomosis site would be best tested with an animal model and critical sized 
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defect. Such study would demonstrate the importance of a prevascularized system and 
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